<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Cutaneous adverse events of molecularly targeted therapy and other biologic agents used for cancer therapy
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Cutaneous adverse events of molecularly targeted therapy and other biologic agents used for cancer therapy
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Cutaneous adverse events of molecularly targeted therapy and other biologic agents used for cancer therapy
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Katherine T Steele, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Alina Markova, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Reed E Drews, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Maja Mockenhaupt, MD, PhD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Rosamaria Corona, MD, DSc
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Oct 23, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Over the last three decades, novel antineoplastic therapy strategies have emerged that exploit molecular abnormalities that exist in certain types of cancer. These drugs are collectively referred to as "molecularly targeted agents." Many of these agents, particularly those interfering with signal transduction (eg, epidermal growth factor receptor [EGFR] inhibitors, multitargeted tyrosine kinase inhibitors [TKIs], BRAF inhibitors), are associated with prominent dermatologic adverse events that may impact quality of life and dosing [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p>
         This topic will review the dermatologic toxicities seen with several classes of molecularly targeted agents. Cutaneous reaction patterns seen with conventional cytotoxic agents and checkpoint inhibitor immunotherapies used for advanced melanoma and other solid and hematologic tumors are discussed elsewhere. Infusion reactions to monoclonal antibodies used for cancer therapy and conventional chemotherapy agents are also discussed separately.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/2090.html" rel="external">
          "Cutaneous adverse effects of conventional chemotherapy agents"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/96368.html" rel="external">
          "Toxicities associated with immune checkpoint inhibitors", section on 'Dermatologic and mucosal toxicity'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/2835.html" rel="external">
          "Infusion reactions to systemic chemotherapy"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/2811.html" rel="external">
          "Infusion-related reactions to therapeutic monoclonal antibodies used for cancer therapy"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          EGFR INHIBITORS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The array of drugs that inhibit the epidermal growth factor receptor (EGFR) include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Monoclonal antibodies:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_general" data-topicid="9209" href="/z/d/drug information/9209.html" rel="external">
          Cetuximab
         </a>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_general" data-topicid="10336" href="/z/d/drug information/10336.html" rel="external">
          Panitumumab
         </a>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_general" data-topicid="105609" href="/z/d/drug information/105609.html" rel="external">
          Necitumumab
         </a>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_general" data-topicid="85639" href="/z/d/drug information/85639.html" rel="external">
          Pertuzumab
         </a>
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Oral small molecules:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_general" data-topicid="8736" href="/z/d/drug information/8736.html" rel="external">
          Erlotinib
         </a>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_general" data-topicid="8712" href="/z/d/drug information/8712.html" rel="external">
          Gefitinib
         </a>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_general" data-topicid="90144" href="/z/d/drug information/90144.html" rel="external">
          Afatinib
         </a>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_general" data-topicid="10093" href="/z/d/drug information/10093.html" rel="external">
          Lapatinib
         </a>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_general" data-topicid="119171" href="/z/d/drug information/119171.html" rel="external">
          Dacomitinib
         </a>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_general" data-topicid="105441" href="/z/d/drug information/105441.html" rel="external">
          Osimertinib
         </a>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_general" data-topicid="114008" href="/z/d/drug information/114008.html" rel="external">
          Neratinib
         </a>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_general" data-topicid="132715" href="/z/d/drug information/132715.html" rel="external">
          Mobocertinib
         </a>
        </p>
        <p>
        </p>
        <p>
         As a group, these drugs are associated with prominent dermatologic adverse events, the most common of which is a papulopustular acneiform eruption  (
         <a class="graphic graphic_table graphicRef57215" href="/z/d/graphic/57215.html" rel="external">
          table 1
         </a>
         ) [
         <a href="#rid2">
          2
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/15764.html" rel="external">
          "Acneiform eruption secondary to epidermal growth factor receptor (EGFR) and MEK inhibitors"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h2">
          Acneiform eruption
         </span>
         <span class="headingEndMark">
          —
         </span>
         The most common cutaneous reaction pattern with EGFR inhibitors is a diffuse, papulopustular acneiform eruption, which is noted in more than two-thirds of patients receiving any of these agents (severe in 10 to 20 percent) [
         <a href="#rid3">
          3-6
         </a>
         ]. The eruption consists of erythematous, follicular papules and pustules, typically without comedones. (See
         <a class="medical medical_review" href="/z/d/html/15764.html" rel="external">
          "Acneiform eruption secondary to epidermal growth factor receptor (EGFR) and MEK inhibitors"
         </a>
         .)
        </p>
        <p>
         The acneiform eruption is often dose dependent and typically begins early, within one to two weeks of treatment initiation  (
         <a class="graphic graphic_picture graphicRef55753 graphicRef121768 graphicRef121769" href="/z/d/graphic/55753.html" rel="external">
          picture 1A-C
         </a>
         ) [
         <a href="#rid7">
          7,8
         </a>
         ]. The lesions typically occur on the face, scalp, chest, and back, sparing the extremities. Scaling of the interfollicular skin may also be present. Significant pruritus accompanies the cutaneous eruption in up to one-third of patients [
         <a href="#rid9">
          9
         </a>
         ].
        </p>
        <p>
         Studies note a consistent positive correlation between the severity of the acneiform rash and antitumor activity [
         <a href="#rid10">
          10-13
         </a>
         ]. The presence of an acneiform eruption is
         <strong>
          not
         </strong>
         a contraindication to continued therapy. In fact, there is evidence that the development of moderate to severe acneiform eruption is associated with an improved survival [
         <a href="#rid14">
          14-17
         </a>
         ]. However, for grade 3 (severe) dermatologic adverse events, dose interruptions and reductions are indicated  (
         <a class="graphic graphic_table graphicRef58603" href="/z/d/graphic/58603.html" rel="external">
          table 2
         </a>
         ). Dose reduction guidelines for most agents are available in their corresponding package inserts. (See
         <a class="medical medical_review" href="/z/d/html/2503.html" rel="external">
          "Systemic therapy for nonoperable metastatic colorectal cancer: Selecting the initial therapeutic approach", section on 'Benefit of cetuximab and panitumumab'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2503.html" rel="external">
          "Systemic therapy for nonoperable metastatic colorectal cancer: Selecting the initial therapeutic approach", section on 'Adverse effects'
         </a>
         .)
        </p>
        <p>
         The clinical course, complications, management, and prevention of the acneiform eruption associated with EGFR inhibitors are discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/15764.html" rel="external">
          "Acneiform eruption secondary to epidermal growth factor receptor (EGFR) and MEK inhibitors"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H6">
         <span class="h2">
          Other reactions
         </span>
         <span class="headingEndMark">
          —
         </span>
         Although the acneiform rash is the most prominent cutaneous adverse reaction, several other skin reactions are reported with anti-EGFR therapies  (
         <a class="graphic graphic_table graphicRef57215" href="/z/d/graphic/57215.html" rel="external">
          table 1
         </a>
         ), including:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Paronychia
         </strong>
         – Cuticular inflammation (often with pyogenic granuloma-like lesions  (
         <a class="graphic graphic_picture graphicRef66462" href="/z/d/graphic/66462.html" rel="external">
          picture 2
         </a>
         )) and secondary bacterial infection (often with
         <em>
          Staphylococcus aureus
         </em>
         ) are frequent adverse events of anti-EGFR agents [
         <a href="#rid18">
          18-20
         </a>
         ]. Onycholysis or onychodystrophy may occur secondary to nail bed inflammation. Treatment options include topical or oral antimicrobials, chemical cauterization, and partial nail avulsion [
         <a href="#rid21">
          21
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/5574.html" rel="external">
          "Paronychia", section on 'Drug-induced paronychia'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/13736.html" rel="external">
          "Pyogenic granuloma (lobular capillary hemangioma)"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Hair abnormalities
         </strong>
         – Hair on the scalp and body may become brittle, fine, and/or curly. Hirsutism, trichomegaly (excessive growth of the eyelashes  (
         <a class="graphic graphic_picture graphicRef129038" href="/z/d/graphic/129038.html" rel="external">
          picture 3
         </a>
         )), and an increase in the length of the eyebrows have been described [
         <a href="#rid22">
          22,23
         </a>
         ]. Reversible alopecia has also been reported with EGFR inhibitors. (See
         <a class="medical medical_review" href="/z/d/html/1156.html" rel="external">
          "Alopecia related to systemic cancer therapy", section on 'Molecularly targeted agents'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Other
         </strong>
         – Other reactions include pruritus, xerosis, mucositis, and photosensitivity [
         <a href="#rid2">
          2,24,25
         </a>
         ]. This constellation of symptoms, in addition to the acneiform eruption, has been labeled PRIDE (
         <strong>
          p
         </strong>
         apulopustules and/or paronychia,
         <strong>
          r
         </strong>
         egulatory abnormalities of hair growth,
         <strong>
          i
         </strong>
         tching, and
         <strong>
          d
         </strong>
         ryness due to
         <strong>
          e
         </strong>
         pidermal growth factor receptor inhibitors) syndrome [
         <a href="#rid26">
          26
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Bullous and exfoliative eruptions, including cases suggestive of Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN), have been rarely reported [
         <a href="#rid27">
          27,28
         </a>
         ]. However, the risk is quite low:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         No increased frequency was observed by the international Registry of Severe Cutaneous Adverse Reactions (RegiSCAR) [
         <a href="#rid29">
          29
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         A systematic review of 117 clinical trials including approximately 9000 patients did not find any additional fatal reactions attributed to
         <a class="drug drug_general" data-topicid="8736" href="/z/d/drug information/8736.html" rel="external">
          erlotinib
         </a>
         ,
         <a class="drug drug_general" data-topicid="9209" href="/z/d/drug information/9209.html" rel="external">
          cetuximab
         </a>
         , or
         <a class="drug drug_general" data-topicid="10336" href="/z/d/drug information/10336.html" rel="external">
          panitumumab
         </a>
         [
         <a href="#rid30">
          30,31
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Radiation dermatitis
         </strong>
         – Increased risk of severe radiation dermatitis is reported in patients treated concomitantly with EGFR inhibitors [
         <a href="#rid32">
          32,33
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/13668.html" rel="external">
          "Radiation dermatitis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H7">
         <span class="h1">
          BCR-ABL TYROSINE KINASE INHIBITORS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Inhibitors of the BCR-ABL fusion protein are multitargeted tyrosine kinase inhibitors (TKIs) that inhibit signal transduction through the BCR-ABL fusion protein, which functions as a tyrosine kinase. Examples of this class of drugs include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Imatinib
         </strong>
         –
         <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">
          Imatinib
         </a>
         is a first-generation multitargeted TKI used for a variety of tumor types, most commonly Philadelphia chromosome-positive chronic myelogenous leukemia (Ph
         <sup>
          +
         </sup>
         CML), which is characterized by the presence of a fusion protein (BCR-ABL, which functions as a tyrosine kinase), and gastrointestinal stromal tumors, which are characterized by
         <em>
          KIT
         </em>
         mutations.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Dasatinib
         </strong>
         <strong>
          ,
         </strong>
         <strong>
          nilotinib
         </strong>
         <strong>
          , and
         </strong>
         <strong>
          bosutinib
         </strong>
         –
         <a class="drug drug_general" data-topicid="8852" href="/z/d/drug information/8852.html" rel="external">
          Dasatinib
         </a>
         ,
         <a class="drug drug_general" data-topicid="9448" href="/z/d/drug information/9448.html" rel="external">
          nilotinib
         </a>
         , and
         <a class="drug drug_general" data-topicid="86371" href="/z/d/drug information/86371.html" rel="external">
          bosutinib
         </a>
         are second-generation TKIs that are only used in patients with Ph
         <sup>
          +
         </sup>
         CML.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Ponatinib
         </strong>
         –
         <a class="drug drug_general" data-topicid="87456" href="/z/d/drug information/87456.html" rel="external">
          Ponatinib
         </a>
         is a third-generation TKI used for the treatment of chronic myeloid leukemia with
         <em>
          BCR-ABL1
         </em>
         T315I mutation. (See
         <a class="medical medical_review" href="/z/d/html/4515.html" rel="external">
          "Treatment of chronic myeloid leukemia in chronic phase after failure of initial therapy"
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         Skin reactions from inhibitors of the BCR-ABL fusion protein are diverse and include maculopapular rash, alopecia, pigmentation disorders, and keratosis pilaris  (
         <a class="graphic graphic_table graphicRef74634" href="/z/d/graphic/74634.html" rel="external">
          table 3
         </a>
         ). More severe skin reaction can rarely occur.
        </p>
        <p class="headingAnchor" id="H1187562394">
         <span class="h2">
          Maculopapular eruption
         </span>
         <span class="headingEndMark">
          —
         </span>
         The most common cutaneous adverse event of TKIs is an exanthematous, maculopapular eruption. In patients taking
         <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">
          imatinib
         </a>
         , the frequency of cutaneous eruptions is dose dependent, ranging from 33 percent at doses less than 400 mg daily to 93 percent with daily doses of 600 mg or more [
         <a href="#rid34">
          34
         </a>
         ]. Although mild cases often spontaneously resolve over time despite drug continuation, more severe skin reactions require discontinuation of treatment for up to two weeks followed by reintroduction at a lower daily dose, with or without a temporary course of an oral corticosteroid [
         <a href="#rid35">
          35-37
         </a>
         ].
        </p>
        <p>
         As with
         <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">
          imatinib
         </a>
         , cutaneous eruptions have been reported with
         <a class="drug drug_general" data-topicid="8852" href="/z/d/drug information/8852.html" rel="external">
          dasatinib
         </a>
         ,
         <a class="drug drug_general" data-topicid="9448" href="/z/d/drug information/9448.html" rel="external">
          nilotinib
         </a>
         ,
         <a class="drug drug_general" data-topicid="87456" href="/z/d/drug information/87456.html" rel="external">
          ponatinib
         </a>
         , and
         <a class="drug drug_general" data-topicid="86371" href="/z/d/drug information/86371.html" rel="external">
          bosutinib
         </a>
         :
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a total of 911 patients reported in phase 1 and 2 studies of
         <a class="drug drug_general" data-topicid="8852" href="/z/d/drug information/8852.html" rel="external">
          dasatinib
         </a>
         , cutaneous eruptions were reported in 35 percent [
         <a href="#rid38">
          38
         </a>
         ]. Reactions included localized and generalized erythema, papular eruptions, "exfoliative rash," and pruritus. Two cases of dasatinib-induced panniculitis have been described [
         <a href="#rid39">
          39
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In phase 1 and 2 studies, the most frequent nonhematologic side effects of
         <a class="drug drug_general" data-topicid="9448" href="/z/d/drug information/9448.html" rel="external">
          nilotinib
         </a>
         were "nonspecific rash" (20 to 28 percent of all patients), pruritus (15 to 24 percent), and dry skin (12 percent) [
         <a href="#rid40">
          40,41
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="87456" href="/z/d/drug information/87456.html" rel="external">
          Ponatinib
         </a>
         , which is available only with limited access in the United States because of a high frequency of venous and arterial thromboembolic phenomena, has been associated with rash and dry skin in up to 40 percent of patients [
         <a href="#rid42">
          42
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/14250.html" rel="external">
          "Cardiovascular toxicities of molecularly targeted antiangiogenic agents", section on 'VEGFR tyrosine kinase inhibitors'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In clinical trials of
         <a class="drug drug_general" data-topicid="86371" href="/z/d/drug information/86371.html" rel="external">
          bosutinib
         </a>
         , adverse skin reactions were reported in 20 to 44 percent of patients and included erythema, maculopapular eruption, pruritic rash, allergic dermatitis, acne, folliculitis, and skin exfoliation [
         <a href="#rid43">
          43,44
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3676746291">
         <span class="h2">
          Severe cutaneous adverse reactions
         </span>
         <span class="headingEndMark">
          —
         </span>
         Severe reactions, including Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) and drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome, have been linked to multitargeted TKIs, in particular to
         <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">
          imatinib
         </a>
         [
         <a href="#rid45">
          45
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2091.html" rel="external">
          "Stevens-Johnson syndrome and toxic epidermal necrolysis: Pathogenesis, clinical manifestations, and diagnosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/16420.html" rel="external">
          "Drug reaction with eosinophilia and systemic symptoms (DRESS)"
         </a>
         .)
        </p>
        <p>
         Acute generalized exanthematous pustulosis (AGEP) and Sweet syndrome (acute febrile neutrophilic dermatosis) have both been associated with
         <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">
          imatinib
         </a>
         therapy [
         <a href="#rid46">
          46-49
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/15761.html" rel="external">
          "Acute generalized exanthematous pustulosis (AGEP)"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/13784.html" rel="external">
          "Sweet syndrome (acute febrile neutrophilic dermatosis): Pathogenesis, clinical manifestations, and diagnosis"
         </a>
         .)
        </p>
        <p>
         Severe reactions usually prompt permanent drug discontinuation, although in some patients, a causal association may be unclear due to comorbidities and concomitant medications. In such cases, the decision to attempt retreatment with
         <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">
          imatinib
         </a>
         depends on the severity of the reaction and whether there are other therapeutic alternatives.
        </p>
        <p class="headingAnchor" id="H979492224">
         <span class="h2">
          Photosensitivity
         </span>
         <span class="headingEndMark">
          —
         </span>
         Photosensitization has been reported in patients treated with
         <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">
          imatinib
         </a>
         [
         <a href="#rid34">
          34,50
         </a>
         ]. In a prospective study of 54 patients treated with imatinib for chronic myeloid leukemia, four (7 percent) developed photosensitivity [
         <a href="#rid34">
          34
         </a>
         ]. Imatinib has also been associated with pseudoporphyria, a bullous photodermatosis with the clinical and histologic features of porphyria cutanea tarda [
         <a href="#rid51">
          51,52
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/13748.html" rel="external">
          "Pseudoporphyria"
         </a>
         .)
        </p>
        <p>
         Photosensitivity has also been reported in patients treated with
         <a class="drug drug_general" data-topicid="112993" href="/z/d/drug information/112993.html" rel="external">
          brigatinib
         </a>
         for anaplastic lymphoma kinase (ALK)-positive, metastatic non-small cell lung cancer [
         <a href="#rid53">
          53
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3579777895">
         <span class="h2">
          Pigmentary changes
         </span>
         <span class="headingEndMark">
          —
         </span>
         A number of patients have noted pigmentary changes of the skin and hair while undergoing treatment with
         <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">
          imatinib
         </a>
         , including both hypopigmentation (in Black patients [
         <a href="#rid54">
          54
         </a>
         ]) and hyperpigmentation [
         <a href="#rid54">
          54-58
         </a>
         ]. In a systematic review and meta-analysis, the incidence of all-grade pigmentary changes of the skin with imatinib monotherapy was 23 percent [
         <a href="#rid59">
          59
         </a>
         ]. As the KIT receptor is known to play a role in melanogenesis and in melanocyte homeostasis [
         <a href="#rid60">
          60
         </a>
         ], the photosensitivity and pigmentary changes may represent direct physiologic responses by skin melanocytes.
        </p>
        <p class="headingAnchor" id="H216789401">
         <span class="h2">
          Other
         </span>
         <span class="headingEndMark">
          —
         </span>
         In early clinical trials, up to 60 percent of patients treated with
         <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">
          imatinib
         </a>
         had edema, typically in a periorbital distribution [
         <a href="#rid61">
          61
         </a>
         ]. Induction of psoriasiform eruptions and exacerbations of psoriasis have occurred in patients treated with imatinib [
         <a href="#rid34">
          34,62,63
         </a>
         ]. In a prospective study of 54 patients treated with imatinib for chronic myeloid leukemia, four developed a psoriasiform eruption; two had a known history of psoriasis [
         <a href="#rid34">
          34
         </a>
         ]. However, improvement of psoriasis has also been reported in one patient receiving imatinib for a gastrointestinal stromal tumor [
         <a href="#rid64">
          64
         </a>
         ].
        </p>
        <p>
         Other miscellaneous reactions that have been reported in patients receiving
         <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">
          imatinib
         </a>
         include small vessel vasculitis, erythema nodosum, a graft-versus-host-like skin reaction [
         <a href="#rid65">
          65
         </a>
         ], an exfoliative dermatitis with fever and nonfollicular pustules [
         <a href="#rid34">
          34
         </a>
         ], lichenoid drug eruption [
         <a href="#rid66">
          66
         </a>
         ], and a single report of hand-foot syndrome [
         <a href="#rid67">
          67
         </a>
         ]. Keratosis pilaris and xerosis are also frequent with TKIs that inhibit signal transduction through the BCR-ABL fusion protein, likely related to concomitant platelet-derived growth factor receptor (PDGFR)-alpha inhibition [
         <a href="#rid68">
          68
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H948429834">
         <span class="h1">
          VEGFR/PDGFR INHIBITORS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Vascular endothelial growth factor receptor (VEGFR)/platelet-derived growth factor receptor (PDGFR) inhibitors are a group of small molecule tyrosine kinase inhibitors (TKIs) that target a number of tyrosine receptors and tyrosine kinases involved in tumor growth and angiogenesis, including VEGFR, PDGFR, fibroblast growth factor receptor (FGFR), and rearranged during transfection (RET). These include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="10277" href="/z/d/drug information/10277.html" rel="external">
          Sorafenib
         </a>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="10305" href="/z/d/drug information/10305.html" rel="external">
          Sunitinib
         </a>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="17141" href="/z/d/drug information/17141.html" rel="external">
          Axitinib
         </a>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9524" href="/z/d/drug information/9524.html" rel="external">
          Pazopanib
         </a>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="86690" href="/z/d/drug information/86690.html" rel="external">
          Regorafenib
         </a>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="87299" href="/z/d/drug information/87299.html" rel="external">
          Cabozantinib
         </a>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="16484" href="/z/d/drug information/16484.html" rel="external">
          Vandetanib
         </a>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="99962" href="/z/d/drug information/99962.html" rel="external">
          Lenvatinib
         </a>
        </p>
        <p>
        </p>
        <p>
         These agents, which are used for the treatment of a variety of tumors (including renal cell carcinoma, hepatocellular carcinoma, and thyroid cancer), are associated with a variety of cutaneous effects, which are summarized in the table  (
         <a class="graphic graphic_table graphicRef74634" href="/z/d/graphic/74634.html" rel="external">
          table 3
         </a>
         ).
        </p>
        <p class="headingAnchor" id="H10">
         <span class="h2">
          Hand-foot skin reaction
         </span>
         <span class="headingEndMark">
          —
         </span>
         Hand-foot skin reaction (HFSR) is the most common cutaneous adverse effect of multitargeted VEGFR TKIs. Its frequency appears to be higher with
         <a class="drug drug_general" data-topicid="10277" href="/z/d/drug information/10277.html" rel="external">
          sorafenib
         </a>
         and
         <a class="drug drug_general" data-topicid="86690" href="/z/d/drug information/86690.html" rel="external">
          regorafenib
         </a>
         compared with other VEGFR inhibitors [
         <a href="#rid69">
          69-74
         </a>
         ]. Overall, all-grade and high-grade HFSR occurs in approximately 35 and 10 percent of patients, respectively [
         <a href="#rid75">
          75,76
         </a>
         ], and differs in its clinical presentation and histologic appearance from the acral erythema caused by other conventional chemotherapy drugs [
         <a href="#rid77">
          77,78
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2090.html" rel="external">
          "Cutaneous adverse effects of conventional chemotherapy agents", section on 'Toxic erythema of chemotherapy'
         </a>
         .)
        </p>
        <p>
         HFSR typically presents with focal, hyperkeratotic, callus-like lesions on an erythematous base in areas of pressure or friction, such as the fingertips, heels and metatarsal areas, and over joints  (
         <a class="graphic graphic_picture graphicRef109140 graphicRef81824 graphicRef109135" href="/z/d/graphic/109140.html" rel="external">
          picture 4A-C
         </a>
         ). The clinical and histologic appearance of HFSR differs from the classic form of acral erythema that is associated with conventional cytotoxic chemotherapy agents, which is most often characterized by a symmetric edema and erythema of the palms and soles that may progress to blistering and necrosis, with loss of the epidermis and crusting  (
         <a class="graphic graphic_picture graphicRef77501" href="/z/d/graphic/77501.html" rel="external">
          picture 5
         </a>
         and
         <a class="graphic graphic_picture graphicRef79857" href="/z/d/graphic/79857.html" rel="external">
          picture 6
         </a>
         ) [
         <a href="#rid58">
          58,69,70,79,80
         </a>
         ]. Although HFSR is not included in the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE) as its own category, "palmoplantar erythrodysesthesia" can be used to grade HFSR  (
         <a class="graphic graphic_table graphicRef73474" href="/z/d/graphic/73474.html" rel="external">
          table 4
         </a>
         ).
        </p>
        <p>
         The management and prevention of HFSR are discussed in detail separately and summarized in the algorithm  (
         <a class="graphic graphic_algorithm graphicRef109178" href="/z/d/graphic/109178.html" rel="external">
          algorithm 1
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/103060.html" rel="external">
          "Hand-foot skin reaction induced by multitargeted tyrosine kinase inhibitors", section on 'Management'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/103060.html" rel="external">
          "Hand-foot skin reaction induced by multitargeted tyrosine kinase inhibitors", section on 'Prevention'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H176858976">
         <span class="h2">
          Hair changes
         </span>
         <span class="headingEndMark">
          —
         </span>
         Diffuse, reversible alopecia has been described in up to 50 percent of patients treated with
         <a class="drug drug_general" data-topicid="10277" href="/z/d/drug information/10277.html" rel="external">
          sorafenib
         </a>
         but less frequently in those treated with
         <a class="drug drug_general" data-topicid="10305" href="/z/d/drug information/10305.html" rel="external">
          sunitinib
         </a>
         (5 to 21 percent),
         <a class="drug drug_general" data-topicid="9524" href="/z/d/drug information/9524.html" rel="external">
          pazopanib
         </a>
         (8 to 10 percent), or
         <a class="drug drug_general" data-topicid="17141" href="/z/d/drug information/17141.html" rel="external">
          axitinib
         </a>
         (4 percent) [
         <a href="#rid2">
          2,71,81,82
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/1156.html" rel="external">
          "Alopecia related to systemic cancer therapy", section on 'Molecularly targeted agents'
         </a>
         .)
        </p>
        <p>
         Reversible hair depigmentation can occur during treatment with
         <a class="drug drug_general" data-topicid="10305" href="/z/d/drug information/10305.html" rel="external">
          sunitinib
         </a>
         and
         <a class="drug drug_general" data-topicid="9524" href="/z/d/drug information/9524.html" rel="external">
          pazopanib
         </a>
         [
         <a href="#rid2">
          2
         </a>
         ]. In a phase 3 trial in which 290 patients with renal cell carcinoma were treated with pazopanib, changes in hair color occurred in 38 percent of treated patients and skin hypopigmentation was noted in 3 percent [
         <a href="#rid83">
          83
         </a>
         ]. In a meta-analysis of 11 trials, the relative risk of all-grade alopecia and hair color changes in cancer patients treated with pazopanib was 1.75 (95% CI 1.33-2.31) and 4.54 (95% CI 3.67-5.62), respectively [
         <a href="#rid84">
          84
         </a>
         ].
        </p>
        <p>
         It is postulated that pigmentary changes associated with
         <a class="drug drug_general" data-topicid="9524" href="/z/d/drug information/9524.html" rel="external">
          pazopanib
         </a>
         may result from alterations in melanocyte proliferation or function secondary to the inhibition of KIT [
         <a href="#rid85">
          85
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1656409228">
         <span class="h2">
          Squamoproliferative lesions
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="10277" href="/z/d/drug information/10277.html" rel="external">
          Sorafenib
         </a>
         has been associated with cutaneous squamoproliferative lesions, including keratoacanthomas (KAs) and squamous cell carcinomas (SCCs) [
         <a href="#rid86">
          86-91
         </a>
         ]. In a retrospective study of 131 patients receiving sorafenib for metastatic renal cell carcinoma, seven were diagnosed with SCC and two with KA [
         <a href="#rid87">
          87
         </a>
         ]. Another report described the appearance of 22 squamoproliferative lesions in 13 patients within nine months of initiating sorafenib [
         <a href="#rid86">
          86
         </a>
         ]. One was described as a classic invasive SCC, five as KA-like SCC, and 16 as classic KA. Prospective studies are necessary to clarify the risk and natural history of sorafenib-induced, squamoproliferative lesions.
        </p>
        <p>
         Squamoproliferative lesions that develop during
         <a class="drug drug_general" data-topicid="10277" href="/z/d/drug information/10277.html" rel="external">
          sorafenib
         </a>
         therapy should be treated similarly to lesions that develop in patients not receiving the drug (usually with complete surgical excision). However, spontaneous regression of KAs has been reported after discontinuation of the drug and also in a few patients who continued therapy [
         <a href="#rid86">
          86,92
         </a>
         ]. Definitive guidelines for continuing versus discontinuing sorafenib in patients who develop SCCs or KAs while on therapy have not been established. Close clinical follow-up during treatment is warranted. (See
         <a class="medical medical_review" href="/z/d/html/5339.html" rel="external">
          "Treatment and prognosis of low-risk cutaneous squamous cell carcinoma (cSCC)"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H12">
         <span class="h2">
          Other cutaneous effects
         </span>
         <span class="headingEndMark">
          —
         </span>
         A wide range of other cutaneous adverse effects have been described in patients treated with VEGFR inhibitors. Examples include the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Sorafenib
         </strong>
         <strong>
          and
         </strong>
         <strong>
          sunitinib
         </strong>
         – Treatment with
         <a class="drug drug_general" data-topicid="10277" href="/z/d/drug information/10277.html" rel="external">
          sorafenib
         </a>
         and
         <a class="drug drug_general" data-topicid="10305" href="/z/d/drug information/10305.html" rel="external">
          sunitinib
         </a>
         has been associated with a variety of cutaneous adverse effects, including seborrheic dermatitis-like facial and scalp erythema, scalp dysesthesia, and subungual splinter hemorrhages [
         <a href="#rid71">
          71,82
         </a>
         ]; eruptive, melanocytic lesions [
         <a href="#rid93">
          93,94
         </a>
         ]; Stevens-Johnson syndrome (SJS); mucositis; geographic tongue [
         <a href="#rid95">
          95
         </a>
         ]; erythema multiforme [
         <a href="#rid96">
          96
         </a>
         ] and erythema multiforme-like eruptions [
         <a href="#rid97">
          97,98
         </a>
         ]; periungual erythema [
         <a href="#rid99">
          99
         </a>
         ]; acquired perforating dermatosis [
         <a href="#rid100">
          100
         </a>
         ]; xerosis; and exanthematous rashes [
         <a href="#rid101">
          101
         </a>
         ]. Sunitinib may induce facial edema and pyoderma gangrenosum, a rare, noninfectious neutrophilic dermatosis [
         <a href="#rid102">
          102-104
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/13782.html" rel="external">
          "Pyoderma gangrenosum: Pathogenesis, clinical features, and diagnosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Vandetanib
         </strong>
         – Seborrheic dermatitis, acneiform eruption, dry skin, pruritus, photosensitivity, or HFSR have been reported in 28 to 71 percent of patients treated with
         <a class="drug drug_general" data-topicid="16484" href="/z/d/drug information/16484.html" rel="external">
          vandetanib
         </a>
         ; they were severe (grade 3 or worse) in 3 to 6 percent [
         <a href="#rid105">
          105-110
         </a>
         ]. Paronychia, genital eruptions resembling intertrigo, photodistributed lichenoid drug eruption, and subacute cutaneous lupus erythematosus have also been reported [
         <a href="#rid111">
          111
         </a>
         ]. Severe skin reactions, some leading to death, have been reported with this agent [
         <a href="#rid112">
          112,113
         </a>
         ]. Patients should be counseled to wear sunscreen and protective clothing when exposed to the sun.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Regorafenib
         </strong>
         –
         <a class="drug drug_general" data-topicid="86690" href="/z/d/drug information/86690.html" rel="external">
          Regorafenib
         </a>
         targets VEGFR-1, VEGFR-2, and VEGFR-3, in addition to RET, KIT, PDGFR-alpha and PDGFR-beta, FGFR1 and FGFR2, and several other membrane-bound and intracellular kinases that are involved in normal cellular function and in pathologic processes. It is approved in the United States for the treatment of refractory metastatic colorectal cancer. In a phase 3 trial (the CORRECT trial), rash/desquamation was reported in 26 percent (versus 4 percent with placebo), and it was severe in 6 versus 0 percent [
         <a href="#rid114">
          114
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/129349.html" rel="external">
          "Systemic therapy for nonoperable metastatic colorectal cancer: Approach to later lines of systemic therapy", section on 'Regorafenib'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Cabozantinib
         </strong>
         – Hair depigmentation, alopecia, dry skin, scrotal erythema/ulceration, and subungual splinter hemorrhages have been reported with
         <a class="drug drug_general" data-topicid="87299" href="/z/d/drug information/87299.html" rel="external">
          cabozantinib
         </a>
         , which is approved in the United States for the treatment of advanced medullary thyroid cancer, hepatocellular carcinoma, and renal cell carcinoma [
         <a href="#rid115">
          115,116
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2188.html" rel="external">
          "Medullary thyroid cancer: Systemic therapy and immunotherapy"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H4173740661">
         <span class="h1">
          FGFR INHIBITORS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Selective fibroblast growth factor receptor (FGFR) inhibitors are small molecule tyrosine kinase inhibitors (TKIs) approved for the treatment of cholangiocarcinoma and urothelial carcinoma. These include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="131754" href="/z/d/drug information/131754.html" rel="external">
          Infigratinib
         </a>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="127947" href="/z/d/drug information/127947.html" rel="external">
          Pemigatinib
         </a>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="121054" href="/z/d/drug information/121054.html" rel="external">
          Erdafitinib
         </a>
        </p>
        <p>
        </p>
        <p>
         Dermatologic toxicities associated with FGFR inhibitors include hand-foot skin reaction (HFSR) (see
         <a class="local">
          'Hand-foot skin reaction'
         </a>
         above), stomatitis and xerostomia, nail changes (eg, paronychia, onychomadesis), and alopecia [
         <a href="#rid117">
          117
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2655715842">
         <span class="h1">
          BRAF INHIBITORS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The BRAF inhibitors are serine-threonine kinase inhibitors that act as kinase inhibitors in mutant
         <em>
          BRAF
         </em>
         . They include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="16798" href="/z/d/drug information/16798.html" rel="external">
          Vemurafenib
         </a>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="89686" href="/z/d/drug information/89686.html" rel="external">
          Dabrafenib
         </a>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="118325" href="/z/d/drug information/118325.html" rel="external">
          Encorafenib
         </a>
         (second-generation BRAF inhibitor)
        </p>
        <p>
        </p>
        <p>
         All three agents are approved for the treatment of metastatic melanoma with a V600E
         <em>
          BRAF
         </em>
         mutation. Cutaneous toxicities are common with these agents and include a wide range of manifestations, including nonspecific rash (maculopapular eruption), phototoxicity, and squamoproliferative lesions [
         <a href="#rid118">
          118
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/15408.html" rel="external">
          "Systemic treatment of metastatic melanoma with BRAF and other molecular alterations", section on 'Dabrafenib plus trametinib'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2407328513">
         <span class="h2">
          Maculopapular rash
         </span>
         <span class="headingEndMark">
          —
         </span>
         A maculopapular eruption is the most common skin reaction associated with BRAF inhibitors. In a meta-analysis of nine randomized trials of
         <a class="drug drug_general" data-topicid="16798" href="/z/d/drug information/16798.html" rel="external">
          vemurafenib
         </a>
         , the overall prevalences of all-grade rash and high-grade rash were 45 percent (95% CI 0.34-0.57) and 12 percent (95% CI 0.03-0.38), respectively [
         <a href="#rid119">
          119
         </a>
         ]. A granulomatous dermatitis, presenting as a widespread eruption of grouped, papular lesions coalescing into plaques, has been reported in a few patients months after starting treatment with vemurafenib [
         <a href="#rid120">
          120
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2877031621">
         <span class="h2">
          Phototoxic reaction
         </span>
         <span class="headingEndMark">
          —
         </span>
         The phototoxic reaction associated with
         <a class="drug drug_general" data-topicid="16798" href="/z/d/drug information/16798.html" rel="external">
          vemurafenib
         </a>
         appears to be caused by ultraviolet A (UVA) radiation and may be prevented with the use of broad-spectrum sunscreens  (
         <a class="graphic graphic_table graphicRef73127" href="/z/d/graphic/73127.html" rel="external">
          table 5
         </a>
         ) [
         <a href="#rid121">
          121
         </a>
         ]. A meta-analysis of eight randomized trials (4095 patients) found an overall prevalence of all-grade phototoxic reaction of 30 percent (95% CI 0.23-0.38) among patients treated with vemurafenib.
        </p>
        <p class="headingAnchor" id="H1609463336">
         <span class="h2">
          Squamoproliferative lesions
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients treated with BRAF inhibitors frequently develop keratinocytic, proliferative lesions, including cutaneous squamous cell carcinoma (cSCC), keratoacanthoma (KA), and verrucous lesions. A meta-analysis of seven randomized trials found a prevalence of cSCC and KA of 18 percent (95% CI 0.12-0.26) and 10 percent (95% CI 0.06-0.15), respectively, among patients taking
         <a class="drug drug_general" data-topicid="16798" href="/z/d/drug information/16798.html" rel="external">
          vemurafenib
         </a>
         [
         <a href="#rid119">
          119
         </a>
         ]. In patients taking
         <a class="drug drug_general" data-topicid="89686" href="/z/d/drug information/89686.html" rel="external">
          dabrafenib
         </a>
         , verrucous lesions with low to moderate epidermal dysplasia have been reported in up to 66 percent and KAs or well-differentiated cSCCs in 6 to 26 percent [
         <a href="#rid118">
          118,122-124
         </a>
         ].
        </p>
        <p>
         These squamoproliferative lesions, which are thought to be induced by a paradoxical activation of the mitogen-activated protein kinase (MAPK) pathway, appear in weeks to a few months after initiating treatment, are fast growing, are widely distributed on the body, and may occur in sun-protected sites [
         <a href="#rid125">
          125
         </a>
         ]. In a series of 134 patients with metastatic melanoma treated with
         <a class="drug drug_general" data-topicid="89686" href="/z/d/drug information/89686.html" rel="external">
          dabrafenib
         </a>
         or
         <a class="drug drug_general" data-topicid="16798" href="/z/d/drug information/16798.html" rel="external">
          vemurafenib
         </a>
         , 32 patients (24 percent) developed one or multiple cSCCs, most of which were in the first three months of treatment [
         <a href="#rid126">
          126
         </a>
         ]. The risk of developing cSCC increased with age, with cSCCs arising in 30 percent or more of patients older than 60 years [
         <a href="#rid126">
          126
         </a>
         ].
        </p>
        <p>
         Interestingly, skin papilloma and cSCC occur less frequently in patients treated with the combination of
         <a class="drug drug_general" data-topicid="118325" href="/z/d/drug information/118325.html" rel="external">
          encorafenib
         </a>
         plus
         <a class="drug drug_general" data-topicid="118324" href="/z/d/drug information/118324.html" rel="external">
          binimetinib
         </a>
         compared with encorafenib or
         <a class="drug drug_general" data-topicid="16798" href="/z/d/drug information/16798.html" rel="external">
          vemurafenib
         </a>
         as monotherapy. In a randomized, phase 3 trial including 577 patients with
         <em>
          BRAF
         </em>
         -mutant melanoma, cSCC developed in 4, 8, and 17 percent of patients receiving encorafenib plus binimetinib, encorafenib alone, or vemurafenib alone, respectively [
         <a href="#rid127">
          127
         </a>
         ].
        </p>
        <p>
         The skin tumors that develop in patients treated with these agents are managed with surgical excision, and patients are usually able to continue treatment without dose adjustment [
         <a href="#rid128">
          128
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2890978617">
         <span class="h2">
          Hair changes
         </span>
         <span class="headingEndMark">
          —
         </span>
         Alopecia is one of the most common adverse reactions of BRAF inhibitors. It has been reported in over 50 percent of patients receiving
         <a class="drug drug_general" data-topicid="118325" href="/z/d/drug information/118325.html" rel="external">
          encorafenib
         </a>
         and nearly 40 percent of patients receiving
         <a class="drug drug_general" data-topicid="16798" href="/z/d/drug information/16798.html" rel="external">
          vemurafenib
         </a>
         [
         <a href="#rid129">
          129,130
         </a>
         ]. Changes in hair structure and color have been reported in patients taking
         <a class="drug drug_general" data-topicid="89686" href="/z/d/drug information/89686.html" rel="external">
          dabrafenib
         </a>
         [
         <a href="#rid124">
          124
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3942083938">
         <span class="h2">
          Palmoplantar keratoderma
         </span>
         <span class="headingEndMark">
          —
         </span>
         In clinical trials, palmoplantar keratoderma has been reported in 15 to 25 percent of patients receiving BRAF inhibitors [
         <a href="#rid124">
          124,129,131
         </a>
         ]. Grade 1 to 2 and grade 3 hand-foot skin reaction (HFSR) have been reported in 38 and 14 percent of patients treated with
         <a class="drug drug_general" data-topicid="118325" href="/z/d/drug information/118325.html" rel="external">
          encorafenib
         </a>
         , respectively [
         <a href="#rid129">
          129
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3393062406">
         <span class="h2">
          Other
         </span>
         <span class="headingEndMark">
          —
         </span>
         Other cutaneous adverse events associated with BRAF inhibitors include hyperkeratosis, palmoplantar erythrodysesthesia, acrochordons, keratosis pilaris, actinic keratoses, lichenoid keratoses, papillomas, seborrheic keratoses, and pyogenic granulomas [
         <a href="#rid127">
          127,132-136
         </a>
         ].
         <a class="drug drug_general" data-topicid="16798" href="/z/d/drug information/16798.html" rel="external">
          Vemurafenib
         </a>
         has also been associated with radiation enhancement when radiation therapy was administered concurrently [
         <a href="#rid137">
          137,138
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/13668.html" rel="external">
          "Radiation dermatitis"
         </a>
         .)
        </p>
        <p>
         Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) has been reported in patients taking
         <a class="drug drug_general" data-topicid="16798" href="/z/d/drug information/16798.html" rel="external">
          vemurafenib
         </a>
         [
         <a href="#rid139">
          139-141
         </a>
         ]. Grover's disease (transient acantholytic dermatosis) has been reported in up to 27 percent of patients receiving
         <a class="drug drug_general" data-topicid="89686" href="/z/d/drug information/89686.html" rel="external">
          dabrafenib
         </a>
         [
         <a href="#rid124">
          124
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/5566.html" rel="external">
          "Grover's disease (transient and persistent acantholytic dermatosis)"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1399328005">
         <span class="h1">
          BRAF PLUS MEK INHIBITORS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Orally bioavailable inhibitors of mitogen-activated protein kinase (MAPK) enzymes (MEK1 and MEK2) include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="89685" href="/z/d/drug information/89685.html" rel="external">
          Trametinib
         </a>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="105354" href="/z/d/drug information/105354.html" rel="external">
          Cobimetinib
         </a>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="118324" href="/z/d/drug information/118324.html" rel="external">
          Binimetinib
         </a>
        </p>
        <p>
        </p>
        <p>
         They are approved for the treatment of unresectable or metastatic melanoma with a
         <em>
          BRAF
         </em>
         V600E or V600K mutation
         <strong>
          in combination
         </strong>
         with the BRAF inhibitors
         <a class="drug drug_general" data-topicid="16798" href="/z/d/drug information/16798.html" rel="external">
          vemurafenib
         </a>
         ,
         <a class="drug drug_general" data-topicid="89686" href="/z/d/drug information/89686.html" rel="external">
          dabrafenib
         </a>
         , and
         <a class="drug drug_general" data-topicid="118325" href="/z/d/drug information/118325.html" rel="external">
          encorafenib
         </a>
         [
         <a href="#rid142">
          142,143
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/15408.html" rel="external">
          "Systemic treatment of metastatic melanoma with BRAF and other molecular alterations", section on 'Choice of BRAF plus MEK inhibitor therapy'
         </a>
         .)
        </p>
        <p>
         Cutaneous adverse effects of MEK inhibitors are common and include acneiform eruption, pruritus, and xerosis [
         <a href="#rid131">
          131,144,145
         </a>
         ]. Data from studies of combination therapy with
         <a class="drug drug_general" data-topicid="89686" href="/z/d/drug information/89686.html" rel="external">
          dabrafenib
         </a>
         plus
         <a class="drug drug_general" data-topicid="89685" href="/z/d/drug information/89685.html" rel="external">
          trametinib
         </a>
         for advanced melanoma indicate that the combination therapy is associated with a marked reduction of cutaneous toxicities compared with
         <a class="drug drug_general" data-topicid="16798" href="/z/d/drug information/16798.html" rel="external">
          vemurafenib
         </a>
         or dabrafenib alone [
         <a href="#rid123">
          123,146,147
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a phase 3 study including 350 patients treated with
         <a class="drug drug_general" data-topicid="89686" href="/z/d/drug information/89686.html" rel="external">
          dabrafenib
         </a>
         plus
         <a class="drug drug_general" data-topicid="89685" href="/z/d/drug information/89685.html" rel="external">
          trametinib
         </a>
         and 349 patients treated with
         <a class="drug drug_general" data-topicid="16798" href="/z/d/drug information/16798.html" rel="external">
          vemurafenib
         </a>
         alone, skin toxicities were less frequent in the combination therapy group than in the vemurafenib group: rash (22 versus 43 percent), photosensitivity reaction (4 versus 22 percent), hand-foot syndrome (4 versus 25 percent), skin papillomas (2 versus 23 percent), cutaneous squamous cell carcinoma (cSCC) and keratoacanthoma (KA; 1 versus 18 percent), and hyperkeratosis (4 versus 25 percent) [
         <a href="#rid146">
          146
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In another phase 3, randomized trial including 211 patients treated with
         <a class="drug drug_general" data-topicid="89686" href="/z/d/drug information/89686.html" rel="external">
          dabrafenib
         </a>
         plus
         <a class="drug drug_general" data-topicid="89685" href="/z/d/drug information/89685.html" rel="external">
          trametinib
         </a>
         and 212 patients treated with dabrafenib alone, cutaneous adverse events occurred less frequently in the combination therapy group than in the dabrafenib alone group: hyperkeratosis (7 versus 35 percent), alopecia (9 versus 28 percent), skin papilloma (2 versus 22 percent), and cSCC/KA (2 versus 7 percent) [
         <a href="#rid147">
          147
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         In a phase 2, randomized trial including 192 patients treated with
         <a class="drug drug_general" data-topicid="118325" href="/z/d/drug information/118325.html" rel="external">
          encorafenib
         </a>
         plus
         <a class="drug drug_general" data-topicid="118324" href="/z/d/drug information/118324.html" rel="external">
          binimetinib
         </a>
         , 194 patients treated with encorafenib alone, and 191 patients treated with
         <a class="drug drug_general" data-topicid="16798" href="/z/d/drug information/16798.html" rel="external">
          vemurafenib
         </a>
         alone, cutaneous adverse events occurred less frequently in the combination therapy group than in the encorafenib and vemurafenib groups: rash (22, 41, and 53 percent, respectively), palmoplantar keratoderma (9, 26, and 16 percent, respectively), palmoplantar erythrodysesthesia (7, 52, and 14 percent, respectively), skin papilloma (7, 10, and 19 percent, respectively), and cSCC/KA (3, 8, and 17 percent, respectively) [
         <a href="#rid129">
          129
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1119797869">
         <span class="h1">
          MET INHIBITORS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Photosensitivity reactions have been reported with
         <a class="drug drug_general" data-topicid="128126" href="/z/d/drug information/128126.html" rel="external">
          capmatinib
         </a>
         , a mesenchymal-epithelial transition (MET) kinase inhibitor approved for the treatment of locally advanced non-small cell lung cancer carrying the MET exon 14 skipping mutation that are resistant to first- or second-generation epidermal growth factor receptor (EGFR) inhibitors [
         <a href="#rid148">
          148
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1930773425">
         <span class="h1">
          PI3K INHIBITORS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Phosphoinositide 3-kinase (PI3K) is a family of highly conserved enzymes involved in the intracellular PI3K/Akt/mammalian target of rapamycin (mTOR) signaling pathway. There are three classes of PI3K kinases (class I [further divided into IA and IB], class II, and class III) and four isoforms (alpha, beta, gamma, delta). Hyperactivation of the PI3K pathway is involved in a variety of human cancers [
         <a href="#rid149">
          149
         </a>
         ]. Class IA PI3K inhibitors include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="96416" href="/z/d/drug information/96416.html" rel="external">
          Idelalisib
         </a>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="114897" href="/z/d/drug information/114897.html" rel="external">
          Copanlisib
         </a>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="119167" href="/z/d/drug information/119167.html" rel="external">
          Duvelisib
         </a>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="119171" href="/z/d/drug information/119171.html" rel="external">
          Dacomitinib
         </a>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="121400" href="/z/d/drug information/121400.html" rel="external">
          Alpelisib
         </a>
        </p>
        <p>
        </p>
        <p>
         <a class="drug drug_general" data-topicid="96416" href="/z/d/drug information/96416.html" rel="external">
          Idelalisib
         </a>
         and
         <a class="drug drug_general" data-topicid="114897" href="/z/d/drug information/114897.html" rel="external">
          copanlisib
         </a>
         are approved in the United States for the treatment of patients with relapsed or refractory chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) and relapsed or refractory follicular lymphoma [
         <a href="#rid150">
          150,151
         </a>
         ].
         <a class="drug drug_general" data-topicid="119167" href="/z/d/drug information/119167.html" rel="external">
          Duvelisib
         </a>
         is approved for the treatment of CLL and SLL [
         <a href="#rid152">
          152
         </a>
         ].
         <a class="drug drug_general" data-topicid="119171" href="/z/d/drug information/119171.html" rel="external">
          Dacomitinib
         </a>
         is indicated for the first-line treatment of patients with metastatic non-small cell lung cancer [
         <a href="#rid153">
          153
         </a>
         ].
         <a class="drug drug_general" data-topicid="121400" href="/z/d/drug information/121400.html" rel="external">
          Alpelisib
         </a>
         is approved for the treatment of breast cancer in combination with aromatase inhibitors [
         <a href="#rid154">
          154
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A meta-analysis of 16 randomized trials found that the overall rates of any grade and severe grade (grade ≥3) cutaneous adverse events in patients treated with any PI3K inhibitors were 29 and 7 percent, respectively [
         <a href="#rid155">
          155
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Mucocutaneous adverse reactions, including maculopapular rash and oral mucositis, have been reported in approximately 14 and 23 percent of patients, respectively, treated with
         <a class="drug drug_general" data-topicid="114897" href="/z/d/drug information/114897.html" rel="external">
          copanlisib
         </a>
         and in 20 to 40 percent and 16 percent of patients, respectively, treated with
         <a class="drug drug_general" data-topicid="119167" href="/z/d/drug information/119167.html" rel="external">
          duvelisib
         </a>
         [
         <a href="#rid156">
          156-159
         </a>
         ]. A maculopapular rash has been reported in up to 30 percent of patients treated with
         <a class="drug drug_general" data-topicid="121400" href="/z/d/drug information/121400.html" rel="external">
          alpelisib
         </a>
         [
         <a href="#rid160">
          160
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Maculopapular rash and exfoliative skin reactions have been reported in 78 and 7 percent of patients, respectively, treated with
         <a class="drug drug_general" data-topicid="119171" href="/z/d/drug information/119171.html" rel="external">
          dacomitinib
         </a>
         [
         <a href="#rid153">
          153
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Serious cutaneous reactions, including drug reaction with eosinophilia and systemic symptoms (DRESS) and toxic epidermal necrolysis (TEN), have been reported in 5 percent of patients treated with
         <a class="drug drug_general" data-topicid="119167" href="/z/d/drug information/119167.html" rel="external">
          duvelisib
         </a>
         [
         <a href="#rid152">
          152
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H150805729">
         <span class="h1">
          CDK 4/6 INHIBITORS
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="99759" href="/z/d/drug information/99759.html" rel="external">
          Palbociclib
         </a>
         [
         <a href="#rid161">
          161,162
         </a>
         ],
         <a class="drug drug_general" data-topicid="115098" href="/z/d/drug information/115098.html" rel="external">
          abemaciclib
         </a>
         [
         <a href="#rid163">
          163
         </a>
         ], and
         <a class="drug drug_general" data-topicid="112288" href="/z/d/drug information/112288.html" rel="external">
          ribociclib
         </a>
         [
         <a href="#rid164">
          164
         </a>
         ] are cyclin-dependent kinase 4/6 (CDK 4/6) inhibitors approved for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, advanced or metastatic breast cancer. They are used in combination with an aromatase inhibitor (palbociclib, abemaciclib, ribociclib),
         <a class="drug drug_general" data-topicid="8784" href="/z/d/drug information/8784.html" rel="external">
          fulvestrant
         </a>
         (palbociclib, abemaciclib), or monotherapy (abemaciclib).
        </p>
        <p>
         Alopecia, maculopapular rash, and pruritus have been reported with CDK 4/6 inhibitors.
        </p>
        <p class="headingAnchor" id="H1995679199">
         <span class="h1">
          JAK INHIBITORS
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="17096" href="/z/d/drug information/17096.html" rel="external">
          Ruxolitinib
         </a>
         is an orally bioavailable inhibitor of Janus kinase (JAK) 1/2 involved in cytokine signaling and hematopoiesis. Ruxolitinib is approved for the treatment of intermediate or high-risk myelofibrosis; polycythemia vera; and steroid-refractory, acute graft-versus-host disease.
        </p>
        <p>
         Increased risk of nonmelanoma skin cancer has been reported with
         <a class="drug drug_general" data-topicid="17096" href="/z/d/drug information/17096.html" rel="external">
          ruxolitinib
         </a>
         [
         <a href="#rid165">
          165,166
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1271584358">
         <span class="h1">
          BTK INHIBITORS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Orally bioavailable, irreversible inhibitors of Bruton's tyrosine kinase (BTK), an integral component of the B cell receptor pathway, include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Ibrutinib
         </strong>
         <strong>
         </strong>
         –
         <a class="drug drug_general" data-topicid="91587" href="/z/d/drug information/91587.html" rel="external">
          Ibrutinib
         </a>
         is a first-generation BTK inhibitor approved by the US Food and Drug Administration (FDA) for the treatment of mantle cell lymphoma, marginal zone lymphoma, chronic lymphocytic leukemia (CLL), and chronic graft-versus-host disease [
         <a href="#rid167">
          167
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Acalabrutinib
         </strong>
         <strong>
          and
         </strong>
         <strong>
          zanubrutinib
         </strong>
         –
         <a class="drug drug_general" data-topicid="115440" href="/z/d/drug information/115440.html" rel="external">
          Acalabrutinib
         </a>
         and
         <a class="drug drug_general" data-topicid="126183" href="/z/d/drug information/126183.html" rel="external">
          zanubrutinib
         </a>
         are second-generation BTK inhibitors approved for relapsed or refractory mantle cell lymphoma [
         <a href="#rid168">
          168,169
         </a>
         ]. Zanubrutinib is also approved for the treatment of relapsed or refractory CLL and small lymphocytic lymphoma (SLL).
        </p>
        <p>
        </p>
        <p>
         Cutaneous adverse effects of BTK inhibitors include petechial to purpuric skin eruptions and nail and hair changes [
         <a href="#rid170">
          170
         </a>
         ]. The overall incidence of dermatologic toxicities is reduced with second-generation BTK inhibitors [
         <a href="#rid171">
          171
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Petechiae and bruising
         </strong>
         – Petechiae and bruising are reported to occur in up to 50 to 54 percent of patients treated with
         <a class="drug drug_general" data-topicid="91587" href="/z/d/drug information/91587.html" rel="external">
          ibrutinib
         </a>
         ,
         <a class="drug drug_general" data-topicid="115440" href="/z/d/drug information/115440.html" rel="external">
          acalabrutinib
         </a>
         , and
         <a class="drug drug_general" data-topicid="126183" href="/z/d/drug information/126183.html" rel="external">
          zanubrutinib
         </a>
         [
         <a href="#rid172">
          172
         </a>
         ]. One study described mild, petechial eruptions, which did not require skin-directed therapy or ibrutinib dose adjustments, as well as palpable, purpuric eruptions, which improved with topical steroids, oral steroids, and/or temporary interruption of ibrutinib [
         <a href="#rid173">
          173
         </a>
         ]. The BTK inhibitor-associated bleeding diathesis is thought to be due to the inhibition of the platelet BTK, which is involved in collagen-mediated platelet activation [
         <a href="#rid174">
          174,175
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Nail and hair changes
         </strong>
         – Nail changes, including onychoschizia (lamellar splitting of the nail) and onychorrhexis (longitudinal ridging), have been reported in approximately two-thirds of patients after 6 to 12 months of treatment with
         <a class="drug drug_general" data-topicid="91587" href="/z/d/drug information/91587.html" rel="external">
          ibrutinib
         </a>
         [
         <a href="#rid176">
          176
         </a>
         ]. Hair changes include straightening and softening or increased curliness. These effects are postulated to be specific to ibrutinib,
         <a class="drug drug_general" data-topicid="115440" href="/z/d/drug information/115440.html" rel="external">
          acalabrutinib
         </a>
         , and
         <a class="drug drug_general" data-topicid="126183" href="/z/d/drug information/126183.html" rel="external">
          zanubrutinib
         </a>
         , as they covalently bind to the cysteine residue at the active site of BTK, and disulfide bonds in hair and nail keratins are known to be important for their integrity.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Skin infections
         </strong>
         – Opportunistic skin infections with herpes simplex and herpes zoster reactivations and
         <em>
          S. aureus
         </em>
         superinfection (presenting as folliculitis) are promoted by BTK inhibitor-associated B cell dysfunction, induced neutropenia, and reduction in macrophagic phagocytosis and are greatest during the first year of therapy, with gradual secondary restoration of cellular and humoral immunity [
         <a href="#rid171">
          171
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         A papulopustular eruption similar to the acneiform eruption of epidermal growth factor receptor (EGFR) inhibitors has been described in patients taking
         <a class="drug drug_general" data-topicid="91587" href="/z/d/drug information/91587.html" rel="external">
          ibrutinib
         </a>
         [
         <a href="#rid177">
          177
         </a>
         ]. Ibrutinib may also induce panniculitis, presenting as well-defined, erythematous, tender nodules on the legs [
         <a href="#rid178">
          178,179
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2270802035">
         <span class="h1">
          CCR4 INHIBITORS
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="118738" href="/z/d/drug information/118738.html" rel="external">
          Mogamulizumab
         </a>
         is a C-C chemokine receptor type 4 (CCR4)-directed monoclonal antibody approved by the US Food and Drug Administration (FDA) for the treatment of relapsed or refractory mycosis fungoides or Sézary syndrome [
         <a href="#rid180">
          180
         </a>
         ]. CCR4, expressed on the surface of tumor cells in T cell malignancies, is involved in lymphocyte cell homing to the skin:
        </p>
        <p>
         Rash is one of the most common adverse events associated with
         <a class="drug drug_general" data-topicid="118738" href="/z/d/drug information/118738.html" rel="external">
          mogamulizumab
         </a>
         (mogamulizumab-associated rash), occurring in 25 percent of patients, with 18 percent of these being severe (grade 3). It typically occurs after 15 to 31 weeks of therapy and can present as a lichenoid, psoriasiform, or pustular eruption. Biopsy may be indicated to distinguish drug eruption from disease progression.
        </p>
        <p>
         Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) have been reported in &lt;1 percent of patients. SJS/TEN is thought to occur due to drug-induced depletion of CCR4-expressing FOXP3
         <sup>
          +
         </sup>
         T cells, leading to uncontrolled, cytotoxic CD8
         <sup>
          +
         </sup>
         T cells [
         <a href="#rid181">
          181
         </a>
         ].
        </p>
        <p>
         Treatment with
         <a class="drug drug_general" data-topicid="118738" href="/z/d/drug information/118738.html" rel="external">
          mogamulizumab
         </a>
         should be discontinued for life-threatening grade 4 rash or for any SJS/TEN. If SJS/TEN is suspected, do not resume unless SJS/TEN has been excluded and the cutaneous adverse event has resolved to grade 1 or less [
         <a href="#rid180">
          180
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3481245785">
         <span class="h1">
          FLT3 INHIBITORS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The FMS-like tyrosine kinase 3 (
         <em>
          FLT3
         </em>
         ) gene is mutated in 30 percent of patients with acute myeloid leukemia (AML), of which nearly a quarter demonstrate internal tandem duplications (ITDs). The FLT3-ITD mutation is associated with an increased risk of relapse and poor prognosis. FLT3 inhibitors induce terminal differentiation of and direct cytotoxicity to
         <em>
          FLT3
         </em>
         -mutant myeloblasts [
         <a href="#rid182">
          182
         </a>
         ].
        </p>
        <p>
         FLT3 inhibitors include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="10277" href="/z/d/drug information/10277.html" rel="external">
          Sorafenib
         </a>
         , lestaurtinib,
         <a class="drug drug_general" data-topicid="112991" href="/z/d/drug information/112991.html" rel="external">
          midostaurin
         </a>
         (first-generation multikinase inhibitors).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="142055" href="/z/d/drug information/142055.html" rel="external">
          Quizartinib
         </a>
         , crenolanib,
         <a class="drug drug_general" data-topicid="119861" href="/z/d/drug information/119861.html" rel="external">
          gilteritinib
         </a>
         (next-generation inhibitors); they are more potent and have less off-target effects compared with first-generation agents.
        </p>
        <p>
        </p>
        <p>
         The adverse events associated with
         <a class="drug drug_general" data-topicid="10277" href="/z/d/drug information/10277.html" rel="external">
          sorafenib
         </a>
         are reviewed above. (See
         <a class="local">
          'VEGFR/PDGFR inhibitors'
         </a>
         above.)
        </p>
        <p>
         Cutaneous adverse events associated with other FLT3 inhibitors include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Petechiae, hyperhidrosis, and xerosis
         </strong>
         – Petechiae, hyperhidrosis, and xerosis have been associated with
         <a class="drug drug_general" data-topicid="112991" href="/z/d/drug information/112991.html" rel="external">
          midostaurin
         </a>
         , an orally bioavailable, first-generation multikinase inhibitor approved for the treatment of newly diagnosed AML that is
         <em>
          FLT3
         </em>
         mutation positive in combination with standard
         <a class="drug drug_general" data-topicid="9314" href="/z/d/drug information/9314.html" rel="external">
          cytarabine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9326" href="/z/d/drug information/9326.html" rel="external">
          daunorubicin
         </a>
         induction, and cytarabine consolidation; aggressive systemic mastocytosis; systemic mastocytosis with associated hematologic neoplasms; or mast cell leukemia [
         <a href="#rid183">
          183
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Peripheral edema and rash
         </strong>
         – Peripheral edema and rash have been reported with
         <a class="drug drug_general" data-topicid="119861" href="/z/d/drug information/119861.html" rel="external">
          gilteritinib
         </a>
         , an orally bioavailable, next-generation FLT3 inhibitor approved for the treatment of relapsed or refractory AML with
         <em>
          FLT3
         </em>
         mutation:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         In the phase 3 ADMIRAL trial, peripheral edema and rash were reported as treatment-emergent adverse events in 24 and 14 percent of patients, respectively [
         <a href="#rid184">
          184
         </a>
         ]. Among 319 patients across three clinical trials,
         <a class="drug drug_general" data-topicid="119861" href="/z/d/drug information/119861.html" rel="external">
          gilteritinib
         </a>
         was associated with peripheral edema and rash in 40 and 36 percent of patients, respectively [
         <a href="#rid185">
          185
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         A meta-analysis of 2656 patients treated with five different FLT3 inhibitors (
         <a class="drug drug_general" data-topicid="10277" href="/z/d/drug information/10277.html" rel="external">
          sorafenib
         </a>
         , lestaurtinib,
         <a class="drug drug_general" data-topicid="112991" href="/z/d/drug information/112991.html" rel="external">
          midostaurin
         </a>
         ,
         <a class="drug drug_general" data-topicid="119861" href="/z/d/drug information/119861.html" rel="external">
          gilteritinib
         </a>
         , and
         <a class="drug drug_general" data-topicid="142055" href="/z/d/drug information/142055.html" rel="external">
          quizartinib
         </a>
         ) found an overall increased risk of rash, desquamation, petechiae, and pruritus with FLT3 inhibitors compared with controls (relative risk [RR] 1.55, 95% CI 1.28-1.87) [
         <a href="#rid186">
          186
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Neutrophilic dermatoses
         </strong>
         – Neutrophilic dermatoses, including panniculitis and Sweet syndrome, have also been associated with FLT3 inhibitors. FLT3 inhibition, which leads to terminal differentiation of myeloblasts, may cause differentiation syndrome with associated neutrophilic dermatosis [
         <a href="#rid182">
          182,187,188
         </a>
         ]. Neutrophilic dermatoses may require treatment dose reduction, interruption, or discontinuation. (See
         <a class="medical medical_review" href="/z/d/html/5571.html" rel="external">
          "Neutrophilic dermatoses"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/86567.html" rel="external">
          "Sweet syndrome (acute febrile neutrophilic dermatosis): Management and prognosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H4113306809">
         <span class="h1">
          IDH INHIBITORS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Isocitrate dehydrogenase (IDH) 1 and 2 are mutated in 6 to 10 percent and 9 to 13 percent of patients, respectively, with acute myeloid leukemia (AML) [
         <a href="#rid189">
          189
         </a>
         ]. These
         <em>
          IDH1/2
         </em>
         mutations block normal cellular differentiation and drive tumorigenesis [
         <a href="#rid190">
          190
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Ivosidenib
         </strong>
         –
         <a class="drug drug_general" data-topicid="118520" href="/z/d/drug information/118520.html" rel="external">
          Ivosidenib
         </a>
         is an oral, selective, small molecule IDH1 inhibitor indicated for the treatment of newly diagnosed AML in patients ≥75 years or with comorbidities that preclude use of intensive induction chemotherapy or for relapsed or refractory AML with a susceptible
         <em>
          IDH1
         </em>
         mutation.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Enasidenib
         </strong>
         –
         <a class="drug drug_general" data-topicid="114206" href="/z/d/drug information/114206.html" rel="external">
          Enasidenib
         </a>
         is an oral, selective, small molecule inhibitor of IDH2 indicated for the treatment of relapsed or refractory AML with a susceptible
         <em>
          IDH2
         </em>
         mutation.
        </p>
        <p>
        </p>
        <p>
         Peripheral edema has been reported in 39 to 43 percent of patients treated with
         <a class="drug drug_general" data-topicid="118520" href="/z/d/drug information/118520.html" rel="external">
          ivosidenib
         </a>
         and in 21 percent of patients treated with
         <a class="drug drug_general" data-topicid="114206" href="/z/d/drug information/114206.html" rel="external">
          enasidenib
         </a>
         [
         <a href="#rid191">
          191,192
         </a>
         ]. Rash and pruritus were reported in 14 to 26 percent and 14 percent of patients, respectively, treated with ivosidenib [
         <a href="#rid191">
          191
         </a>
         ].
        </p>
        <p>
         Edema and rash may present as manifestations of differentiation syndrome, resulting from IDH1/2 therapy. Treatment with IDH1/2 inhibitors may remove the differentiation block in the malignant myeloid clone, leading to a rapid increase in differentiated neutrophils associated with a constellation of findings, including constitutional symptoms, culture-negative fevers, pleural/pericardial effusions, edema, weight gain, hypotension, renal dysfunction, and rash at a time of marked leukocytosis, known as differentiation syndrome [
         <a href="#rid190">
          190
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1272279957">
         <span class="h1">
          BCL2 INHIBITORS
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="107696" href="/z/d/drug information/107696.html" rel="external">
          Venetoclax
         </a>
         is an orally bioavailable inhibitor of B cell lymphoma 2 (BCL2), an antiapoptotic protein that is constitutively overexpressed in chronic lymphocytic leukemia (CLL) cells [
         <a href="#rid193">
          193
         </a>
         ]. Venetoclax is approved for the treatment of patients with CLL with 17p deletion who have received at least one prior therapy.
        </p>
        <p>
         Rash has been reported in 14 percent of CLL patients on
         <a class="drug drug_general" data-topicid="107696" href="/z/d/drug information/107696.html" rel="external">
          venetoclax
         </a>
         with concurrent
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         and in 22 percent of patients on venetoclax post-therapy with
         <a class="drug drug_general" data-topicid="96416" href="/z/d/drug information/96416.html" rel="external">
          idelalisib
         </a>
         [
         <a href="#rid193">
          193
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2636668679">
         <span class="h1">
          ANTIBODY-DRUG CONJUGATES
         </span>
         <span class="headingEndMark">
          —
         </span>
         Antibody-drug conjugates (ADCs) are composed of a monoclonal antibody, targeting an antigen expressed on tumor cells, covalently attached to a cytotoxic drug via a chemical linker. ADCs that target a tumor antigen that is also physiologically expressed in normal skin or mucosal tissue may cause associated toxicities due to cytotoxic drug delivery to normal tissues.
        </p>
        <p>
         <a class="drug drug_general" data-topicid="126407" href="/z/d/drug information/126407.html" rel="external">
          Enfortumab vedotin
         </a>
         is a nectin-4-directed ADC approved for the treatment of patients with locally advanced or metastatic urothelial cancer. Nectin-4 is expressed in both urothelial tumor and normal skin tissue. During the first cycle of treatment, approximately 50 percent of patients may experience a cutaneous reaction, most frequently pruritus and a maculopapular eruption consisting of erythematous, scaly, pruritic papules predominately located in intertriginous and acral areas [
         <a href="#rid194">
          194
         </a>
         ]. These eruptions may rarely progress to blistering and Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN)-like eruptions.
        </p>
        <p>
         Treatment interruption of
         <a class="drug drug_general" data-topicid="126407" href="/z/d/drug information/126407.html" rel="external">
          enfortumab vedotin
         </a>
         , topical steroids, and/or systemic steroids with supportive wound care may be indicated [
         <a href="#rid194">
          194
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H757138">
         <span class="h1">
          SUMMARY
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          EGFR inhibitors
         </strong>
         – Epidermal growth factor receptor (EGFR) inhibitors (eg,
         <a class="drug drug_general" data-topicid="9209" href="/z/d/drug information/9209.html" rel="external">
          cetuximab
         </a>
         ,
         <a class="drug drug_general" data-topicid="10336" href="/z/d/drug information/10336.html" rel="external">
          panitumumab
         </a>
         ,
         <a class="drug drug_general" data-topicid="8736" href="/z/d/drug information/8736.html" rel="external">
          erlotinib
         </a>
         ,
         <a class="drug drug_general" data-topicid="8712" href="/z/d/drug information/8712.html" rel="external">
          gefitinib
         </a>
         ,
         <a class="drug drug_general" data-topicid="10093" href="/z/d/drug information/10093.html" rel="external">
          lapatinib
         </a>
         ) are associated with prominent dermatologic adverse events, the most common of which is a papulopustular acneiform eruption  (
         <a class="graphic graphic_table graphicRef57215" href="/z/d/graphic/57215.html" rel="external">
          table 1
         </a>
         ). It typically begins early, within one to two weeks of treatment initiation and is often dose dependent  (
         <a class="graphic graphic_picture graphicRef55753 graphicRef121768 graphicRef121769" href="/z/d/graphic/55753.html" rel="external">
          picture 1A-C
         </a>
         ) [
         <a href="#rid7">
          7,8
         </a>
         ]. The lesions occur on the face, scalp, chest, and back, usually sparing the extremities. Other reactions associated with EGFR inhibitors include paronychia  (
         <a class="graphic graphic_picture graphicRef66462" href="/z/d/graphic/66462.html" rel="external">
          picture 2
         </a>
         ), hair abnormalities, xerosis, mucositis, and photosensitivity. (See
         <a class="local">
          'EGFR inhibitors'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/15764.html" rel="external">
          "Acneiform eruption secondary to epidermal growth factor receptor (EGFR) and MEK inhibitors"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          BCR-ABL tyrosine kinase inhibitors
         </strong>
         – The most common cutaneous adverse event associated with inhibitors of the BCR-ABL fusion protein (eg,
         <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">
          imatinib
         </a>
         ,
         <a class="drug drug_general" data-topicid="8852" href="/z/d/drug information/8852.html" rel="external">
          dasatinib
         </a>
         ,
         <a class="drug drug_general" data-topicid="87456" href="/z/d/drug information/87456.html" rel="external">
          ponatinib
         </a>
         ) is an exanthematous, maculopapular eruption. Severe skin reactions, including Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN), drug reaction with eosinophilia and systemic symptoms (DRESS), acute generalized exanthematous pustulosis (AGEP), and Sweet syndrome, have been reported with imatinib. Other reactions include photosensitivity, pigmentary changes of the skin and hair, edema, psoriasiform eruption, keratosis pilaris, and xerosis. (See
         <a class="local">
          'BCR-ABL tyrosine kinase inhibitors'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          VEGFR/PDGFR inhibitors
         </strong>
         – Vascular endothelial growth factor receptor (VEGFR)/platelet-derived growth factor receptor (PDGFR) inhibitors (eg,
         <a class="drug drug_general" data-topicid="10277" href="/z/d/drug information/10277.html" rel="external">
          sorafenib
         </a>
         ,
         <a class="drug drug_general" data-topicid="10305" href="/z/d/drug information/10305.html" rel="external">
          sunitinib
         </a>
         ,
         <a class="drug drug_general" data-topicid="9524" href="/z/d/drug information/9524.html" rel="external">
          pazopanib
         </a>
         ,
         <a class="drug drug_general" data-topicid="86690" href="/z/d/drug information/86690.html" rel="external">
          regorafenib
         </a>
         ) are most frequently associated with hand-foot skin reaction (HFSR). It typically presents with focal, hyperkeratotic, callus-like lesions on an erythematous base in areas of pressure or friction, such as the fingertips, heels and metatarsal areas, and over joints  (
         <a class="graphic graphic_picture graphicRef109140 graphicRef81824 graphicRef109135" href="/z/d/graphic/109140.html" rel="external">
          picture 4A-C
         </a>
         ). HFSR is discussed in detail separately (see
         <a class="medical medical_review" href="/z/d/html/103060.html" rel="external">
          "Hand-foot skin reaction induced by multitargeted tyrosine kinase inhibitors"
         </a>
         ). Other adverse events include a diffuse, reversible alopecia and changes in hair color, maculopapular rash, desquamation, and xerosis. Sorafenib has also been associated with cutaneous, squamoproliferative lesions, including keratoacanthomas (KAs) and squamous cell carcinomas (SCCs). (See
         <a class="local">
          'VEGFR/PDGFR inhibitors'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          BRAF inhibitors
         </strong>
         – BRAF inhibitors (eg,
         <a class="drug drug_general" data-topicid="16798" href="/z/d/drug information/16798.html" rel="external">
          vemurafenib
         </a>
         ,
         <a class="drug drug_general" data-topicid="89686" href="/z/d/drug information/89686.html" rel="external">
          dabrafenib
         </a>
         ,
         <a class="drug drug_general" data-topicid="118325" href="/z/d/drug information/118325.html" rel="external">
          encorafenib
         </a>
         ) are frequently associated with a maculopapular eruption. Vemurafenib may also cause an ultraviolet A (UVA)-induced phototoxic reaction. Patients treated with BRAF inhibitors frequently develop keratinocytic proliferative lesions, including cutaneous squamous cell carcinoma (cSCC), KA, and verrucal keratotic lesions, which appear weeks to months after initiating treatment. Other reactions include alopecia, palmoplantar keratoderma, palmoplantar erythrodysesthesia, acrochordon, actinic keratosis, and pyogenic granuloma. (See
         <a class="local">
          'BRAF inhibitors'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          MEK inhibitors
         </strong>
         – Cutaneous adverse effects of MEK inhibitors (
         <a class="drug drug_general" data-topicid="89685" href="/z/d/drug information/89685.html" rel="external">
          trametinib
         </a>
         ,
         <a class="drug drug_general" data-topicid="105354" href="/z/d/drug information/105354.html" rel="external">
          cobimetinib
         </a>
         , and
         <a class="drug drug_general" data-topicid="118324" href="/z/d/drug information/118324.html" rel="external">
          binimetinib
         </a>
         ) include acneiform eruption, pruritus, and xerosis. Of note, the cutaneous toxicity of the BRAF-MEK combination therapy is markedly reduced compared with BRAF therapy alone. (See
         <a class="local">
          'BRAF plus MEK inhibitors'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          MET inhibitors
         </strong>
         – Photosensitivity reactions have been reported with
         <a class="drug drug_general" data-topicid="128126" href="/z/d/drug information/128126.html" rel="external">
          capmatinib
         </a>
         , a mesenchymal-epithelial transition (MET) kinase inhibitor. (See
         <a class="local">
          'MET inhibitors'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          PI3K inhibitors
         </strong>
         – Phosphoinositide 3-kinase (PI3K) inhibitors (
         <a class="drug drug_general" data-topicid="96416" href="/z/d/drug information/96416.html" rel="external">
          idelalisib
         </a>
         ,
         <a class="drug drug_general" data-topicid="114897" href="/z/d/drug information/114897.html" rel="external">
          copanlisib
         </a>
         ,
         <a class="drug drug_general" data-topicid="119167" href="/z/d/drug information/119167.html" rel="external">
          duvelisib
         </a>
         ,
         <a class="drug drug_general" data-topicid="119171" href="/z/d/drug information/119171.html" rel="external">
          dacomitinib
         </a>
         , and
         <a class="drug drug_general" data-topicid="121400" href="/z/d/drug information/121400.html" rel="external">
          alpelisib
         </a>
         ) are associated with maculopapular rash and oral mucositis. Serious cutaneous reaction, including DRESS and TEN, have been reported in patients treated with duvelisib. (See
         <a class="local">
          'PI3K inhibitors'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          CDK inhibitors
         </strong>
         – Cyclin-dependent kinase (CDK) 4/6 inhibitors (
         <a class="drug drug_general" data-topicid="99759" href="/z/d/drug information/99759.html" rel="external">
          palbociclib
         </a>
         ,
         <a class="drug drug_general" data-topicid="115098" href="/z/d/drug information/115098.html" rel="external">
          abemaciclib
         </a>
         ,
         <a class="drug drug_general" data-topicid="112288" href="/z/d/drug information/112288.html" rel="external">
          ribociclib
         </a>
         ) are associated with alopecia, maculopapular rash, and pruritus. (See
         <a class="local">
          'CDK 4/6 inhibitors'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          JAK inhibitors
         </strong>
         – The Janus kinase (JAK) inhibitor
         <a class="drug drug_general" data-topicid="17096" href="/z/d/drug information/17096.html" rel="external">
          ruxolitinib
         </a>
         is associated with an increased risk of nonmelanoma skin cancer. (See
         <a class="local">
          'JAK inhibitors'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          BTK inhibitors
         </strong>
         – The Bruton kinase (BTK) inhibitor
         <a class="drug drug_general" data-topicid="91587" href="/z/d/drug information/91587.html" rel="external">
          ibrutinib
         </a>
         is associated with petechiae, bruising, and nail and hair changes. (See
         <a class="local">
          'BTK inhibitors'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          CCR4 inhibitors
         </strong>
         – Rash is one of the most common adverse events associated with the C-C chemokine receptor type 4 (CCR4) inhibitor
         <a class="drug drug_general" data-topicid="118738" href="/z/d/drug information/118738.html" rel="external">
          mogamulizumab
         </a>
         . SJS/TEN, scaly plaques, pustular eruption, folliculitis, and nonspecific or psoriasiform dermatitis have also been reported. (See
         <a class="local">
          'CCR4 inhibitors'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          FLT3 inhibitors
         </strong>
         – FMS-like tyrosine kinase 3 (FLT3) inhibitors (
         <a class="drug drug_general" data-topicid="112991" href="/z/d/drug information/112991.html" rel="external">
          midostaurin
         </a>
         ,
         <a class="drug drug_general" data-topicid="119861" href="/z/d/drug information/119861.html" rel="external">
          gilteritinib
         </a>
         ) are associated with neutrophilic dermatoses. Midostaurin is also associated with petechiae, hyperhidrosis, and xerosis. Gilteritinib may cause peripheral edema, rash, and dermatologic manifestations as part of differentiation syndrome. (See
         <a class="medical medical_review" href="/z/d/html/4351.html" rel="external">
          "Differentiation syndrome associated with treatment of acute leukemia"
         </a>
         and
         <a class="local">
          'FLT3 inhibitors'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          IDH inhibitors
         </strong>
         – Isocitrate dehydrogenase (IDH) inhibitors (
         <a class="drug drug_general" data-topicid="118520" href="/z/d/drug information/118520.html" rel="external">
          ivosidenib
         </a>
         ,
         <a class="drug drug_general" data-topicid="114206" href="/z/d/drug information/114206.html" rel="external">
          enasidenib
         </a>
         ) are associated with peripheral edema, rash, pruritus, and dermatologic manifestations as part of differentiation syndrome. (See
         <a class="local">
          'IDH inhibitors'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          BCL2 inhibitors
         </strong>
         – The B cell lymphoma 2 (BCL2) inhibitor
         <a class="drug drug_general" data-topicid="107696" href="/z/d/drug information/107696.html" rel="external">
          venetoclax
         </a>
         is associated with rash. (See
         <a class="local">
          'BCL2 inhibitors'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Antibody-drug conjugates
         </strong>
         –
         <a class="drug drug_general" data-topicid="126407" href="/z/d/drug information/126407.html" rel="external">
          Enfortumab vedotin
         </a>
         may cause pruritus and a maculopapular eruption predominately located in intertriginous and acral areas. (See
         <a class="local">
          'Antibody-drug conjugates'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1551032231">
         <span class="h1">
          ACKNOWLEDGMENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The UpToDate editorial staff acknowledges Diane MF Savarese, MD, Aimee S Payne, MD, PhD, and Mario E Lacouture, MD, who contributed to earlier versions of this topic review.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Reyes-Habito CM, Roh EK. Cutaneous reactions to chemotherapeutic drugs and targeted therapy for cancer: Part II. Targeted therapy. J Am Acad Dermatol 2014; 71:217.e1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Macdonald JB, Macdonald B, Golitz LE, et al. Cutaneous adverse effects of targeted therapies: Part I: Inhibitors of the cellular membrane. J Am Acad Dermatol 2015; 72:203.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jacot W, Bessis D, Jorda E, et al. Acneiform eruption induced by epidermal growth factor receptor inhibitors in patients with solid tumours. Br J Dermatol 2004; 151:238.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Busam KJ, Capodieci P, Motzer R, et al. Cutaneous side-effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225. Br J Dermatol 2001; 144:1169.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moy B, Goss PE. Lapatinib-associated toxicity and practical management recommendations. Oncologist 2007; 12:756.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jatoi A, Green EM, Rowland KM Jr, et al. Clinical predictors of severe cetuximab-induced rash: observations from 933 patients enrolled in north central cancer treatment group study N0147. Oncology 2009; 77:120.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kimyai-Asadi A, Jih MH. Follicular toxic effects of chimeric anti-epidermal growth factor receptor antibody cetuximab used to treat human solid tumors. Arch Dermatol 2002; 138:129.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Van Doorn R, Kirtschig G, Scheffer E, et al. Follicular and epidermal alterations in patients treated with ZD1839 (Iressa), an inhibitor of the epidermal growth factor receptor. Br J Dermatol 2002; 147:598.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Li T, Perez-Soler R. Skin toxicities associated with epidermal growth factor receptor inhibitors. Target Oncol 2009; 4:107.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351:337.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Peréz-Soler R, Saltz L. Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining? J Clin Oncol 2005; 23:5235.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Agero AL, Dusza SW, Benvenuto-Andrade C, et al. Dermatologic side effects associated with the epidermal growth factor receptor inhibitors. J Am Acad Dermatol 2006; 55:657.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Perez-Soler R. Rash as a surrogate marker for efficacy of epidermal growth factor receptor inhibitors in lung cancer. Clin Lung Cancer 2006; 8 Suppl 1:S7.
          </a>
         </li>
         <li class="breakAll">
          Van Cutsem E, Humblet Y, Gelderblom H, et al. Cetuximab dose-escalation study in patients with metastatic colorectal cancer aith no or slight skin reactions on cetuximab standard dose treatment (EVEREST): pharmacokinetics and efficacy data of a randomized study (abstract). Data presented at the 4th annual ASCO Gastrointestinal Cancers Symposium, Orlando, FL, January 20, 2007.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Peeters M, Siena S, Van Cutsem E, et al. Association of progression-free survival, overall survival, and patient-reported outcomes by skin toxicity and KRAS status in patients receiving panitumumab monotherapy. Cancer 2009; 115:1544.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Berlin J, Van Cutsem E, Peeters M, et al. Predictive value of skin toxicity severity for response to panitumumab in patients with metastatic colorectal cancer (mCRC): pooled analysis of five clinical trials (abstract). J Clin Oncol 2007; 25S: ASCO #4134.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Van Cutsem E, Tejpar S, Vanbeckevoort D, et al. Intrapatient cetuximab dose escalation in metastatic colorectal cancer according to the grade of early skin reactions: the randomized EVEREST study. J Clin Oncol 2012; 30:2861.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Robert C, Sibaud V, Mateus C, et al. Nail toxicities induced by systemic anticancer treatments. Lancet Oncol 2015; 16:e181.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Garden BC, Wu S, Lacouture ME. The risk of nail changes with epidermal growth factor receptor inhibitors: a systematic review of the literature and meta-analysis. J Am Acad Dermatol 2012; 67:400.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Eames T, Grabein B, Kroth J, Wollenberg A. Microbiological analysis of epidermal growth factor receptor inhibitor therapy-associated paronychia. J Eur Acad Dermatol Venereol 2010; 24:958.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lacouture ME, Anadkat MJ, Bensadoun RJ, et al. Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities. Support Care Cancer 2011; 19:1079.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wang SB, Lei KJ, Liu JP, Jia YM. Eyelash trichomegaly following treatment with erlotinib in a non-small cell lung cancer patient: A case report and literature review. Oncol Lett 2015; 10:954.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Borkar DS, Lacouture ME, Basti S. Spectrum of ocular toxicities from epidermal growth factor receptor inhibitors and their intermediate-term follow-up: a five-year review. Support Care Cancer 2013; 21:1167.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ensslin CJ, Rosen AC, Wu S, Lacouture ME. Pruritus in patients treated with targeted cancer therapies: systematic review and meta-analysis. J Am Acad Dermatol 2013; 69:708.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Luu M, Lai SE, Patel J, et al. Photosensitive rash due to the epidermal growth factor receptor inhibitor erlotinib. Photodermatol Photoimmunol Photomed 2007; 23:42.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lacouture ME, Lai SE. The PRIDE (Papulopustules and/or paronychia, Regulatory abnormalities of hair growth, Itching, and Dryness due to Epidermal growth factor receptor inhibitors) syndrome. Br J Dermatol 2006; 155:852.
          </a>
         </li>
         <li class="breakAll">
          Erlotinib hydrochloride tablet. US Food and Drug Administration (FDA) approved product information. US National Library of Medicine. http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=57bccb29-1c47-4c64-ab6a-77960a91cc20 (Accessed on January 07, 2014).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lin WL, Lin WC, Yang JY, et al. Fatal toxic epidermal necrolysis associated with cetuximab in a patient with colon cancer. J Clin Oncol 2008; 26:2779.
          </a>
         </li>
         <li class="breakAll">
          http://regiscar.uni-freiburg.de/index.html (Accessed on May 24, 2012).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jatoi A, Nguyen PL. Do patients die from rashes from epidermal growth factor receptor inhibitors? A systematic review to help counsel patients about holding therapy. Oncologist 2008; 13:1201.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rosen AC, Balagula Y, Raisch DW, et al. Life-threatening dermatologic adverse events in oncology. Anticancer Drugs 2014; 25:225.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tejwani A, Wu S, Jia Y, et al. Increased risk of high-grade dermatologic toxicities with radiation plus epidermal growth factor receptor inhibitor therapy. Cancer 2009; 115:1286.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bonomo P, Loi M, Desideri I, et al. Incidence of skin toxicity in squamous cell carcinoma of the head and neck treated with radiotherapy and cetuximab: A systematic review. Crit Rev Oncol Hematol 2017; 120:98.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Valeyrie L, Bastuji-Garin S, Revuz J, et al. Adverse cutaneous reactions to imatinib (STI571) in Philadelphia chromosome-positive leukemias: a prospective study of 54 patients. J Am Acad Dermatol 2003; 48:201.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Milojkovic D, Short K, Salisbury JR, et al. Dose-limiting dermatological toxicity secondary to imatinib mesylate (STI571) in chronic myeloid leukaemia. Leukemia 2003; 17:1414.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Park SR, Ryu MH, Ryoo BY, et al. Severe Imatinib-Associated Skin Rash in Gastrointestinal Stromal Tumor Patients: Management and Clinical Implications. Cancer Res Treat 2016; 48:162.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kim EJ, Ryu MH, Park SR, et al. Systemic Steroid Treatment for Imatinib-Associated Severe Skin Rash in Patients with Gastrointestinal Stromal Tumor: A Phase II Study. Oncologist 2020; 25:e1785.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Heidary N, Naik H, Burgin S. Chemotherapeutic agents and the skin: An update. J Am Acad Dermatol 2008; 58:545.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Assouline S, Laneuville P, Gambacorti-Passerini C. Panniculitis during dasatinib therapy for imatinib-resistant chronic myelogenous leukemia. N Engl J Med 2006; 354:2623.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kantarjian H, Giles F, Wunderle L, et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med 2006; 354:2542.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kantarjian HM, Giles F, Gattermann N, et al. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood 2007; 110:3540.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cortes JE, Kim DW, Pinilla-Ibarz J, et al. A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. N Engl J Med 2013; 369:1783.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cortes JE, Kantarjian HM, Brümmendorf TH, et al. Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib. Blood 2011; 118:4567.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cortes JE, Kim DW, Kantarjian HM, et al. Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial. J Clin Oncol 2012; 30:3486.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chen CB, Wu MY, Ng CY, et al. Severe cutaneous adverse reactions induced by targeted anticancer therapies and immunotherapies. Cancer Manag Res 2018; 10:1259.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schwarz M, Kreuzer KA, Baskaynak G, et al. Imatinib-induced acute generalized exanthematous pustulosis (AGEP) in two patients with chronic myeloid leukemia. Eur J Haematol 2002; 69:254.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Liu D, Seiter K, Mathews T, et al. Sweet's syndrome with CML cell infiltration of the skin in a patient with chronic-phase CML while taking Imatinib Mesylate. Leuk Res 2004; 28 Suppl 1:S61.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ayirookuzhi SJ, Ma L, Ramshesh P, Mills G. Imatinib-induced sweet syndrome in a patient with chronic myeloid leukemia. Arch Dermatol 2005; 141:368.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sidoroff A, Halevy S, Bavinck JN, et al. Acute generalized exanthematous pustulosis (AGEP)--a clinical reaction pattern. J Cutan Pathol 2001; 28:113.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rousselot P, Larghero J, Raffoux E, et al. Photosensitization in chronic myelogenous leukaemia patients treated with imatinib mesylate. Br J Haematol 2003; 120:1091.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pérez NO, Esturo SV, Viladomiu Edel A, et al. Pseudoporphyria induced by imatinib mesylate. Int J Dermatol 2014; 53:e143.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mahon C, Purvis D, Laughton S, et al. Imatinib mesylate-induced pseudoporphyria in two children. Pediatr Dermatol 2014; 31:603.
          </a>
         </li>
         <li class="breakAll">
          Alunbrig (brigatinib) tablets, for oral use. US FDA approved product information; Lexington, MA: Takeda Pharmaceuticals America, Inc; September 2021. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/208772s012lbl.pdf (Accessed on October 18, 2021).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tsao AS, Kantarjian H, Cortes J, et al. Imatinib mesylate causes hypopigmentation in the skin. Cancer 2003; 98:2483.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Arora B, Kumar L, Sharma A, et al. Pigmentary changes in chronic myeloid leukemia patients treated with imatinib mesylate. Ann Oncol 2004; 15:358.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Leong KW, Lee TC, Goh AS. Imatinib mesylate causes hypopigmentation in the skin. Cancer 2004; 100:2486.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Han H, Yu YY, Wang YH. Imatinib mesylate-induced repigmentation of vitiligo lesions in a patient with recurrent gastrointestinal stromal tumors. J Am Acad Dermatol 2008; 59:S80.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Robert C, Soria JC, Spatz A, et al. Cutaneous side-effects of kinase inhibitors and blocking antibodies. Lancet Oncol 2005; 6:491.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dai J, Belum VR, Wu S, et al. Pigmentary changes in patients treated with targeted anticancer agents: A systematic review and meta-analysis. J Am Acad Dermatol 2017; 77:902.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Longley BJ, Carter EL. SCF-KIT pathway in human epidermal melanocyte homeostasis. J Invest Dermatol 1999; 113:139.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001; 344:1031.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dickens E, Lewis F, Bienz N. Imatinib: a designer drug, another cutaneous complication. Clin Exp Dermatol 2009; 34:603.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Woo SM, Huh CH, Park KC, Youn SW. Exacerbation of psoriasis in a chronic myelogenous leukemia patient treated with imatinib. J Dermatol 2007; 34:724.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Miyagawa S, Fujimoto H, Ko S, et al. Improvement of psoriasis during imatinib therapy in a patient with a metastatic gastrointestinal stromal tumour. Br J Dermatol 2002; 147:406.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Drummond A, Micallef-Eynaud P, Douglas WS, et al. A spectrum of skin reactions caused by the tyrosine kinase inhibitor imatinib mesylate (STI 571, Glivec). Br J Haematol 2003; 120:911.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Penn EH, Chung HJ, Keller M. Imatinib mesylate-induced lichenoid drug eruption. Cutis 2017; 99:189.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Battistella M, Frémont G, Vignon-Pennamen MD, et al. Imatinib-induced hand-foot syndrome in a patient with metastatic gastrointestinal stromal tumor. Arch Dermatol 2008; 144:1400.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Valentine J, Belum VR, Duran J, et al. Incidence and risk of xerosis with targeted anticancer therapies. J Am Acad Dermatol 2015; 72:656.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lacouture ME, Reilly LM, Gerami P, Guitart J. Hand foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinib. Ann Oncol 2008; 19:1955.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Boone SL, Jameson G, Von Hoff D, Lacouture ME. Blackberry-induced hand-foot skin reaction to sunitinib. Invest New Drugs 2009; 27:389.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Autier J, Escudier B, Wechsler J, et al. Prospective study of the cutaneous adverse effects of sorafenib, a novel multikinase inhibitor. Arch Dermatol 2008; 144:886.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bhojani N, Jeldres C, Patard JJ, et al. Toxicities associated with the administration of sorafenib, sunitinib, and temsirolimus and their management in patients with metastatic renal cell carcinoma. Eur Urol 2008; 53:917.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chu D, Lacouture ME, Fillos T, Wu S. Risk of hand-foot skin reaction with sorafenib: a systematic review and meta-analysis. Acta Oncol 2008; 47:176.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007; 356:125.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ding F, Liu B, Wang Y. Risk of hand-foot skin reaction associated with vascular endothelial growth factor-tyrosine kinase inhibitors: A meta-analysis of 57 randomized controlled trials involving 24,956 patients. J Am Acad Dermatol 2020; 83:788.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Belum VR, Serna-Tamayo C, Wu S, Lacouture ME. Incidence and risk of hand-foot skin reaction with cabozantinib, a novel multikinase inhibitor: a meta-analysis. Clin Exp Dermatol 2016; 41:8.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Abdel-Rahman O, Fouad M. Risk of mucocutaneous toxicities in patients with solid tumors treated with sunitinib: a critical review and meta analysis. Expert Rev Anticancer Ther 2015; 15:129.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhang L, Zhou Q, Ma L, et al. Meta-analysis of dermatological toxicities associated with sorafenib. Clin Exp Dermatol 2011; 36:344.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tsai KY, Yang CH, Kuo TT, et al. Hand-foot syndrome and seborrheic dermatitis-like rash induced by sunitinib in a patient with advanced renal cell carcinoma. J Clin Oncol 2006; 24:5786.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Russell IJ, Perkins AT, Michalek JE, Oxybate SXB-26 Fibromyalgia Syndrome Study Group. Sodium oxybate relieves pain and improves function in fibromyalgia syndrome: a randomized, double-blind, placebo-controlled, multicenter clinical trial. Arthritis Rheum 2009; 60:299.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Belum VR, Marulanda K, Ensslin C, et al. Alopecia in patients treated with molecularly targeted anticancer therapies. Ann Oncol 2015; 26:2496.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rini BI, Escudier B, Tomczak P, et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet 2011; 378:1931.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sternberg CN, Davis ID, Mardiak J, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 2010; 28:1061.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Elhalawani H, Heiba M, Abdel-Rahman O. Risk of Distinctive Hair Changes Associated With Pazopanib in Patients With Renal Cell Carcinoma (RCC) Versus Patients Without RCC: A Comparative Systematic Review and Meta-analysis. Clin Genitourin Cancer 2017; 15:e325.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sideras K, Menefee ME, Burton JK, et al. Profound hair and skin hypopigmentation in an African American woman treated with the multi-targeted tyrosine kinase inhibitor pazopanib. J Clin Oncol 2010; 28:e312.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Arnault JP, Wechsler J, Escudier B, et al. Keratoacanthomas and squamous cell carcinomas in patients receiving sorafenib. J Clin Oncol 2009; 27:e59.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dubauskas Z, Kunishige J, Prieto VG, et al. Cutaneous squamous cell carcinoma and inflammation of actinic keratoses associated with sorafenib. Clin Genitourin Cancer 2009; 7:20.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kong HH, Cowen EW, Azad NS, et al. Keratoacanthomas associated with sorafenib therapy. J Am Acad Dermatol 2007; 56:171.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hong DS, Reddy SB, Prieto VG, et al. Multiple squamous cell carcinomas of the skin after therapy with sorafenib combined with tipifarnib. Arch Dermatol 2008; 144:779.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Smith KJ, Haley H, Hamza S, Skelton HG. Eruptive keratoacanthoma-type squamous cell carcinomas in patients taking sorafenib for the treatment of solid tumors. Dermatol Surg 2009; 35:1766.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kwon EJ, Kish LS, Jaworsky C. The histologic spectrum of epithelial neoplasms induced by sorafenib. J Am Acad Dermatol 2009; 61:522.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jantzem H, Dupre-Goetghebeur D, Spindler P, Merrer J. [Sorafenib-induced multiple eruptive keratoacanthomas]. Ann Dermatol Venereol 2009; 136:894.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kong HH, Sibaud V, Chanco Turner ML, et al. Sorafenib-induced eruptive melanocytic lesions. Arch Dermatol 2008; 144:820.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jiménez-Gallo D, Albarrán-Planelles C, Linares-Barrios M, et al. Eruptive melanocytic nevi in a patient undergoing treatment with sunitinib. JAMA Dermatol 2013; 149:624.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hubiche T, Valenza B, Chevreau C, et al. Geographic tongue induced by angiogenesis inhibitors. Oncologist 2013; 18:e16.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ikeda M, Fujita T, Mii S, et al. Erythema multiforme induced by sorafenib for metastatic renal cell carcinoma. Jpn J Clin Oncol 2012; 42:820.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lewin J, Farley-Loftus R, Pomeranz MK. Erythema multiforme-like drug reaction to sorafenib. J Drugs Dermatol 2011; 10:1462.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pichard DC, Cardones AR, Chu EY, et al. Sorafenib-Induced Eruption Mimicking Erythema Multiforme. JAMA Dermatol 2016; 152:227.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Suwattee P, Chow S, Berg BC, Warshaw EM. Sunitinib: a cause of bullous palmoplantar erythrodysesthesia, periungual erythema, and mucositis. Arch Dermatol 2008; 144:123.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Severino-Freire M, Sibaud V, Tournier E, et al. Acquired perforating dermatosis associated with sorafenib therapy. J Eur Acad Dermatol Venereol 2016; 30:328.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Robert C, Mateus C, Spatz A, et al. Dermatologic symptoms associated with the multikinase inhibitor sorafenib. J Am Acad Dermatol 2009; 60:299.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nadauld LD, Miller MB, Srinivas S. Pyoderma gangrenosum with the use of sunitinib. J Clin Oncol 2011; 29:e266.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dean SM, Zirwas M. A Second Case of Sunitinib-associated Pyoderma Gangrenosum. J Clin Aesthet Dermatol 2010; 3:34.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           ten Freyhaus K, Homey B, Bieber T, Wilsmann-Theis D. Pyoderma gangrenosum: another cutaneous side-effect of sunitinib? Br J Dermatol 2008; 159:242.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wells SA Jr, Gosnell JE, Gagel RF, et al. Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Oncol 2010; 28:767.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Robinson BG, Paz-Ares L, Krebs A, et al. Vandetanib (100 mg) in patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Endocrinol Metab 2010; 95:2664.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Natale RB, Thongprasert S, Greco FA, et al. Phase III trial of vandetanib compared with erlotinib in patients with previously treated advanced non-small-cell lung cancer. J Clin Oncol 2011; 29:1059.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Arnold AM, Seymour L, Smylie M, et al. Phase II study of vandetanib or placebo in small-cell lung cancer patients after complete or partial response to induction chemotherapy with or without radiation therapy: National Cancer Institute of Canada Clinical Trials Group Study BR.20. J Clin Oncol 2007; 25:4278.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lee JS, Hirsh V, Park K, et al. Vandetanib Versus placebo in patients with advanced non-small-cell lung cancer after prior therapy with an epidermal growth factor receptor tyrosine kinase inhibitor: a randomized, double-blind phase III trial (ZEPHYR). J Clin Oncol 2012; 30:1114.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Morris GM, Hopewell JW. Epidermal cell kinetics of the pig: a review. Cell Tissue Kinet 1990; 23:271.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Giacchero D, Ramacciotti C, Arnault JP, et al. A new spectrum of skin toxic effects associated with the multikinase inhibitor vandetanib. Arch Dermatol 2012; 148:1418.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yoon J, Oh CW, Kim CY. Stevens-johnson syndrome induced by vandetanib. Ann Dermatol 2011; 23:S343.
          </a>
         </li>
         <li class="breakAll">
          Vandetanib tablet. US Food and Drug Administration (FDA) approved product information. US National Library of Medicine. http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4dc7f0af-77fb-4eec-46b9-dd1c2dcb4525 (Accessed on December 10, 2012).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Grothey A, Van Cutsem E, Sobrero A, et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 2013; 381:303.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Elisei R, Schlumberger MJ, Müller SP, et al. Cabozantinib in progressive medullary thyroid cancer. J Clin Oncol 2013; 31:3639.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zuo RC, Apolo AB, DiGiovanna JJ, et al. Cutaneous adverse effects associated with the tyrosine-kinase inhibitor cabozantinib. JAMA Dermatol 2015; 151:170.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lacouture ME, Sibaud V, Anadkat MJ, et al. Dermatologic Adverse Events Associated with Selective Fibroblast Growth Factor Receptor Inhibitors: Overview, Prevention, and Management Guidelines. Oncologist 2021; 26:e316.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Anforth R, Fernandez-Peñas P, Long GV. Cutaneous toxicities of RAF inhibitors. Lancet Oncol 2013; 14:e11.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chen P, Chen F, Zhou B. Systematic review and meta-analysis of prevalence of dermatological toxicities associated with vemurafenib treatment in patients with melanoma. Clin Exp Dermatol 2019; 44:243.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hui Ong EL, Sinha R, Jmor S, Fearfield L. BRAF Inhibitor-Associated Granulomatous Dermatitis: A Report of 3 Cases. Am J Dermatopathol 2019; 41:214.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dummer R, Rinderknecht J, Goldinger SM. Ultraviolet A and photosensitivity during vemurafenib therapy. N Engl J Med 2012; 366:480.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ascierto PA, Minor D, Ribas A, et al. Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma. J Clin Oncol 2013; 31:3205.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Carlos G, Anforth R, Clements A, et al. Cutaneous Toxic Effects of BRAF Inhibitors Alone and in Combination With MEK Inhibitors for Metastatic Melanoma. JAMA Dermatol 2015; 151:1103.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Anforth RM, Blumetti TC, Kefford RF, et al. Cutaneous manifestations of dabrafenib (GSK2118436): a selective inhibitor of mutant BRAF in patients with metastatic melanoma. Br J Dermatol 2012; 167:1153.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Su F, Viros A, Milagre C, et al. RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N Engl J Med 2012; 366:207.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Anforth R, Menzies A, Byth K, et al. Factors influencing the development of cutaneous squamous cell carcinoma in patients on BRAF inhibitor therapy. J Am Acad Dermatol 2015; 72:809.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dummer R, Ascierto PA, Gogas HJ, et al. Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 2018; 19:1315.
          </a>
         </li>
         <li class="breakAll">
          Zelboraf (vemurafenib) tablet, oral. US FDA approved product information; South San Francisco, CA: Genentech; August 2011. www.accessdata.fda.gov/drugsatfda_docs/label/2011/202429s000lbl.pdf (Accessed on October 11, 2011).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dummer R, Ascierto PA, Gogas HJ, et al. Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2018; 19:603.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sosman JA, Kim KB, Schuchter L, et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med 2012; 366:707.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Livingstone E. Evaluation of cutaneous adverse events of encorafenib and binimetinb: COMMENT on article by Graf et al. J Eur Acad Dermatol Venereol 2019; 33:630.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011; 364:2507.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ribas A, Kim KB, Schuchter LM, et al. BRIM-2: An open-label, multicenter phase II study of vemurafenib in previously treated patients with BRAF V600E mutation-positive metastatic melanoma. J Clin Oncol 2011; 29: Abstract 8509.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sammut SJ, Tomson N, Corrie P. Pyogenic granuloma as a cutaneous adverse effect of vemurafenib. N Engl J Med 2014; 371:1265.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Piraccini BM, Patrizi A, Fanti PA, et al. RASopathic alopecia: hair changes associated with vemurafenib therapy. J Am Acad Dermatol 2015; 72:738.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hauschild A, Grob JJ, Demidov LV, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 2012; 380:358.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Boussemart L, Boivin C, Claveau J, et al. Vemurafenib and radiosensitization. JAMA Dermatol 2013; 149:855.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Boussemart L, Routier E, Mateus C, et al. Prospective study of cutaneous side-effects associated with the BRAF inhibitor vemurafenib: a study of 42 patients. Ann Oncol 2013; 24:1691.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bellón T, Lerma V, González-Valle O, et al. Vemurafenib-induced toxic epidermal necrolysis: possible cross-reactivity with other sulfonamide compounds. Br J Dermatol 2016; 174:621.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jeudy G, Dalac-Rat S, Bonniaud B, et al. Successful switch to dabrafenib after vemurafenib-induced toxic epidermal necrolysis. Br J Dermatol 2015; 172:1454.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sinha R, Lecamwasam K, Purshouse K, et al. Toxic epidermal necrolysis in a patient receiving vemurafenib for treatment of metastatic malignant melanoma. Br J Dermatol 2014; 170:997.
          </a>
         </li>
         <li class="breakAll">
          Mekinist (trametinib) tablets, for oral use. US FDA approved product information; Research Triangle Park, NC: GlaxoSmithKline; May 2013. https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/204114s000lbl.pdf (Accessed on August 13, 2013).
         </li>
         <li class="breakAll">
          Cotellic (cobimetinib) tablets, for oral use. US FDA approved product information; South San Francisco, CA: Genentech USA, Inc; November 2015. www.accessdata.fda.gov/drugsatfda_docs/label/2015/206192s000lbl.pdf (Accessed on November 24, 2015).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kim KB, Kefford R, Pavlick AC, et al. Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor. J Clin Oncol 2013; 31:482.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Flaherty KT, Robert C, Hersey P, et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med 2012; 367:107.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Robert C, Karaszewska B, Schachter J, et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med 2015; 372:30.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Long GV, Flaherty KT, Stroyakovskiy D, et al. Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study. Ann Oncol 2017; 28:1631.
          </a>
         </li>
         <li class="breakAll">
          Capmatinib tablets. United States Prescribing Information. US National Library of Medicine. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213591s000lbl.pdf (Accessed on May 07, 2020).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Noorolyai S, Shajari N, Baghbani E, et al. The relation between PI3K/AKT signalling pathway and cancer. Gene 2019; 698:120.
          </a>
         </li>
         <li class="breakAll">
          Zydelig (idelalisib) tablets, for oral use. US FDA approved product information; Foster City, CA: Gilead Sciences, Inc; July 2014. https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/205858lbl.pdf (Accessed on January 11, 2021).
         </li>
         <li class="breakAll">
          Aliqopa (copanlisib) for injection, for intravenous use. US FDA approved product information; Whippany, NJ: Bayer HealthCare Pharmaceuticals Inc; September 2017. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209936s000lbl.pdf (Accessed on January 11, 2021).
         </li>
         <li class="breakAll">
          Copiktra (duvelisib), capsules for oral use. US FDA approved product information; Needham, MA: Verastem, Inc; September 2018. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211155s000lbl.pdf (Accessed on January 11, 2021).
         </li>
         <li class="breakAll">
          Vizimpro (dacomitinib) tablets, for oral use. US FDA approved product information; New York, NY: Pfizer, Inc; September 2018. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211288s000lbl.pdf (Accessed on January 11, 2021).
         </li>
         <li class="breakAll">
          Piqray (alpelisib) tablets, for oral use. US FDA approved product information; East Hanover, NJ: Novartis Pharmaceuticals Corporation; May 2019. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212526s000lbl.pdf (Accessed on January 11, 2021).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jfri A, Meltzer R, Mostaghimi A, et al. Incidence of Cutaneous Adverse Events With Phosphoinositide 3-Kinase Inhibitors as Adjuvant Therapy in Patients With Cancer: A Systematic Review and Meta-analysis. JAMA Oncol 2022; 8:1635.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Horwitz SM, Koch R, Porcu P, et al. Activity of the PI3K-δ,γ inhibitor duvelisib in a phase 1 trial and preclinical models of T-cell lymphoma. Blood 2018; 131:888.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Flinn IW, Patel M, Oki Y, et al. Duvelisib, an oral dual PI3K-δ, γ inhibitor, shows clinical activity in indolent non-Hodgkin lymphoma in a phase 1 study. Am J Hematol 2018; 93:1311.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Greenwell IB, Ip A, Cohen JB. PI3K Inhibitors: Understanding Toxicity Mechanisms and Management. Oncology (Williston Park) 2017; 31:821.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dreyling M, Morschhauser F, Bouabdallah K, et al. Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma. Ann Oncol 2017; 28:2169.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           André F, Ciruelos E, Rubovszky G, et al. Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer. N Engl J Med 2019; 380:1929.
          </a>
         </li>
         <li class="breakAll">
          Ibrance (palbociclib) capsules, for oral use. US FDA approved product information; New York, NY: Pfizer; March 2017. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/207103s004lbl.pdf (Accessed on March 29, 2021).
         </li>
         <li class="breakAll">
          Ibrance (palbociclib) tablets, for oral use. US FDA approved product information; New York, NY: Pfizer; November 2019. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212436lbl.pdf (Accessed on March 29, 2021).
         </li>
         <li class="breakAll">
          Verzenio (abemaciclib) tablets, for oral use. US FDA approved product information; Indianapolis, IN: Lilly USA, LLC; February 2018. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208855s000lbl.pdf (Accessed on March 29, 2021).
         </li>
         <li class="breakAll">
          KIisqali (ribociclib) tablets, for oral use. US FDA approved product information; East Hanover, NJ: Novartis Pharmaceuticals Corporation; March 2017. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209092s000lbl.pdf (Accessed on March 29, 2021).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Polverelli N, Elli EM, Abruzzese E, et al. Second primary malignancy in myelofibrosis patients treated with ruxolitinib. Br J Haematol 2021; 193:356.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lee GH, Guzman AK, Divito SJ, et al. Cutaneous Squamous-Cell Carcinoma after Treatment with Ruxolitinib or Belumosudil. N Engl J Med 2023; 389:188.
          </a>
         </li>
         <li class="breakAll">
          Imbruvica (ibrutinib) capsules, for oral use. US FDA approved product information; Sunnyvale, CA: Pharmacyclics, Inc; January 2015. www.accessdata.fda.gov/drugsatfda_docs/label/2015/205552s002lbl.pdf (Accessed on December 18, 2019).
         </li>
         <li class="breakAll">
          Calquence (acalabrutinib) capsules, for oral use. US FDA approved product information; Wilmington, DE: AstraZeneca Pharmaceuticals LP; October 2017. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/216387Orig2s000Correctedlbl.pdf (Accessed on January 31, 2023).
         </li>
         <li class="breakAll">
          Brukinsa (zanubrutinib) capsules, for oral use. US FDA approved product information; San Mateo, CA: BeiGene USA, Inc; November 2019. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213217s007lbl.pdf (Accessed on January 31, 2023).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nocco S, Andriano TM, Bose A, et al. Ibrutinib-associated dermatologic toxicities: A systematic review and meta-analysis. Crit Rev Oncol Hematol 2022; 174:103696.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sibaud V, Beylot-Barry M, Protin C, et al. Dermatological Toxicities of Bruton's Tyrosine Kinase Inhibitors. Am J Clin Dermatol 2020; 21:799.
          </a>
         </li>
         <li class="breakAll">
          www.imbruvica.com/docs/librariesprovider2/default-document-library/pdf-downloads/prescribing_information.pdf (Accessed on May 04, 2016).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Iberri DJ, Kwong B, Stevens L, et al. Ibrutinib-Associated Rash: Single-Center Experience of Clinicopathologic Features and Management. Blood 2015; 126:4860.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kamel S, Horton L, Ysebaert L, et al. Ibrutinib inhibits collagen-mediated but not ADP-mediated platelet aggregation. Leukemia 2015; 29:783.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lipsky AH, Farooqui MZ, Tian X, et al. Incidence and risk factors of bleeding-related adverse events in patients with chronic lymphocytic leukemia treated with ibrutinib. Haematologica 2015; 100:1571.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bitar C, Farooqui MZ, Valdez J, et al. Hair and Nail Changes During Long-term Therapy With Ibrutinib for Chronic Lymphocytic Leukemia. JAMA Dermatol 2016; 152:698.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Singer S, Tan SY, Dewan AK, et al. Cutaneous eruptions from ibrutinib resembling epidermal growth factor receptor inhibitor-induced dermatologic adverse events. J Am Acad Dermatol 2023; 88:1271.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fabbro SK, Smith SM, Dubovsky JA, et al. Panniculitis in Patients Undergoing Treatment With the Bruton Tyrosine Kinase Inhibitor Ibrutinib for Lymphoid Leukemias. JAMA Oncol 2015; 1:684.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stewart J, Bayers S, Vandergriff T. Self-limiting Ibrutinib-Induced Neutrophilic Panniculitis. Am J Dermatopathol 2018; 40:e28.
          </a>
         </li>
         <li class="breakAll">
          Poteligeo (mogamulizumab-kpkc) injection, for intravenous use. US FDA approved product information; Bedminster, NJ: Kyowa Kirin, Inc; August 2018. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761051s000lbl.pdf (Accessed on March 29, 2021).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Amakata M, Teraki Y. Depletion of regulatory FoxP3+ T cells in the pathogenesis of Stevens-Johnson syndrome induced by mogamulizumab. Int J Dermatol 2019; 58:e247.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fathi AT, Le L, Hasserjian RP, et al. FLT3 inhibitor-induced neutrophilic dermatosis. Blood 2013; 122:239.
          </a>
         </li>
         <li class="breakAll">
          Rydapt (midostaurin) capsules, for oral use. US FDA approved product information; East Hanover, NJ: Novartis Pharmaceuticals Corporation; April 2017. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/207997s000lbl.pdf (Accessed on March 29, 2021).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Perl AE, Martinelli G, Cortes JE, et al. Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML. N Engl J Med 2019; 381:1728.
          </a>
         </li>
         <li class="breakAll">
          Xospata (gilteritinib) tablets, for oral use. US FDA approved product information; Northbrook, IL: Astellas Pharma US, Inc; May 2019. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211349s001lbl.pdf (Accessed on March 29, 2021).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Majothi S, Adams D, Loke J, et al. FLT3 inhibitors in acute myeloid leukaemia: assessment of clinical effectiveness, adverse events and future research-a systematic review and meta-analysis. Syst Rev 2020; 9:285.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Varadarajan N, Boni A, Elder DE, et al. FLT3 Inhibitor-Associated Neutrophilic Dermatoses. JAMA Dermatol 2016; 152:480.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pulte ED, Norsworthy KJ, Wang Y, et al. FDA Approval Summary: Gilteritinib for Relapsed or Refractory Acute Myeloid Leukemia with a FLT3 Mutation. Clin Cancer Res 2021; 27:3515.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           DiNardo CD, Stein EM, de Botton S, et al. Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML. N Engl J Med 2018; 378:2386.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Birendra KC, DiNardo CD. Evidence for Clinical Differentiation and Differentiation Syndrome in Patients With Acute Myeloid Leukemia and IDH1 Mutations Treated With the Targeted Mutant IDH1 Inhibitor, AG-120. Clin Lymphoma Myeloma Leuk 2016; 16:460.
          </a>
         </li>
         <li class="breakAll">
          Tibsovo (ivosidenib tablets), for oral use. US FDA approved product information; Cambridge, MA: Agios Pharmaceuticals, Inc; May 2019. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211192s001lbl.pdf (Accessed on March 29, 2021).
         </li>
         <li class="breakAll">
          Idhifa (enasidenib) tablets, for oral use. US FDA approved product information; Summit, NJ Celgene Corporation; August 2017. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209606s000lbl.pdf (Accessed on March 29, 2021).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Seymour JF, Kipps TJ, Eichhorst B, et al. Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia. N Engl J Med 2018; 378:1107.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lacouture ME, Patel AB, Rosenberg JE, O'Donnell PH. Management of Dermatologic Events Associated With the Nectin-4-directed Antibody-Drug Conjugate Enfortumab Vedotin. Oncologist 2022; 27:e223.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 2088 Version 72.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25037801" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Cutaneous reactions to chemotherapeutic drugs and targeted therapy for cancer: Part II. Targeted therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25592338" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Cutaneous adverse effects of targeted therapies: Part I: Inhibitors of the cellular membrane.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15270903" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Acneiform eruption induced by epidermal growth factor receptor inhibitors in patients with solid tumours.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11422037" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Cutaneous side-effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17673607" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Lapatinib-associated toxicity and practical management recommendations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19622902" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Clinical predictors of severe cetuximab-induced rash: observations from 933 patients enrolled in north central cancer treatment group study N0147.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11790188" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Follicular toxic effects of chimeric anti-epidermal growth factor receptor antibody cetuximab used to treat human solid tumors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12207609" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Follicular and epidermal alterations in patients treated with ZD1839 (Iressa), an inhibitor of the epidermal growth factor receptor.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19452131" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Skin toxicities associated with epidermal growth factor receptor inhibitors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15269313" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16051966" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17010747" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Dermatologic side effects associated with the epidermal growth factor receptor inhibitors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17239291" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Rash as a surrogate marker for efficacy of epidermal growth factor receptor inhibitors in lung cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17239291" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Rash as a surrogate marker for efficacy of epidermal growth factor receptor inhibitors in lung cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19189371" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Association of progression-free survival, overall survival, and patient-reported outcomes by skin toxicity and KRAS status in patients receiving panitumumab monotherapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Predictive value of skin toxicity severity for response to panitumumab in patients with metastatic colorectal cancer (mCRC): pooled analysis of five clinical trials (abstract)
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22753904" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Intrapatient cetuximab dose escalation in metastatic colorectal cancer according to the grade of early skin reactions: the randomized EVEREST study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25846098" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Nail toxicities induced by systemic anticancer treatments.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22088429" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : The risk of nail changes with epidermal growth factor receptor inhibitors: a systematic review of the literature and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20015177" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Microbiological analysis of epidermal growth factor receptor inhibitor therapy-associated paronychia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21630130" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26622603" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Eyelash trichomegaly following treatment with erlotinib in a non-small cell lung cancer patient: A case report and literature review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23151647" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Spectrum of ocular toxicities from epidermal growth factor receptor inhibitors and their intermediate-term follow-up: a five-year review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23981682" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Pruritus in patients treated with targeted cancer therapies: systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17254038" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Photosensitive rash due to the epidermal growth factor receptor inhibitor erlotinib.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16965448" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : The PRIDE (Papulopustules and/or paronychia, Regulatory abnormalities of hair growth, Itching, and Dryness due to Epidermal growth factor receptor inhibitors) syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16965448" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : The PRIDE (Papulopustules and/or paronychia, Regulatory abnormalities of hair growth, Itching, and Dryness due to Epidermal growth factor receptor inhibitors) syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18509187" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Fatal toxic epidermal necrolysis associated with cetuximab in a patient with colon cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18509187" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Fatal toxic epidermal necrolysis associated with cetuximab in a patient with colon cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18988655" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Do patients die from rashes from epidermal growth factor receptor inhibitors? A systematic review to help counsel patients about holding therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24108082" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Life-threatening dermatologic adverse events in oncology.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19170238" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Increased risk of high-grade dermatologic toxicities with radiation plus epidermal growth factor receptor inhibitor therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29198343" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Incidence of skin toxicity in squamous cell carcinoma of the head and neck treated with radiotherapy and cetuximab: A systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12582389" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Adverse cutaneous reactions to imatinib (STI571) in Philadelphia chromosome-positive leukemias: a prospective study of 54 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12835733" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Dose-limiting dermatological toxicity secondary to imatinib mesylate (STI571) in chronic myeloid leukaemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26323636" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Severe Imatinib-Associated Skin Rash in Gastrointestinal Stromal Tumor Patients: Management and Clinical Implications.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32589310" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Systemic Steroid Treatment for Imatinib-Associated Severe Skin Rash in Patients with Gastrointestinal Stromal Tumor: A Phase II Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18342708" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Chemotherapeutic agents and the skin: An update.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16775249" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Panniculitis during dasatinib therapy for imatinib-resistant chronic myelogenous leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16775235" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17715389" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24180494" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21865346" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22949154" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29844705" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Severe cutaneous adverse reactions induced by targeted anticancer therapies and immunotherapies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12431246" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Imatinib-induced acute generalized exanthematous pustulosis (AGEP) in two patients with chronic myeloid leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15036943" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Sweet's syndrome with CML cell infiltration of the skin in a patient with chronic-phase CML while taking Imatinib Mesylate.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15781678" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Imatinib-induced sweet syndrome in a patient with chronic myeloid leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11168761" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Acute generalized exanthematous pustulosis (AGEP)--a clinical reaction pattern.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12648085" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Photosensitization in chronic myelogenous leukaemia patients treated with imatinib mesylate.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23451912" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Pseudoporphyria induced by imatinib mesylate.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24920470" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Imatinib mesylate-induced pseudoporphyria in two children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24920470" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Imatinib mesylate-induced pseudoporphyria in two children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14635084" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Imatinib mesylate causes hypopigmentation in the skin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14760137" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Pigmentary changes in chronic myeloid leukemia patients treated with imatinib mesylate.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15160360" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Imatinib mesylate causes hypopigmentation in the skin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19119132" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Imatinib mesylate-induced repigmentation of vitiligo lesions in a patient with recurrent gastrointestinal stromal tumors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15992698" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Cutaneous side-effects of kinase inhibitors and blocking antibodies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28918974" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Pigmentary changes in patients treated with targeted anticancer agents: A systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10417634" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : SCF-KIT pathway in human epidermal melanocyte homeostasis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11287972" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19486036" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Imatinib: a designer drug, another cutaneous complication.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17908148" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Exacerbation of psoriasis in a chronic myelogenous leukemia patient treated with imatinib.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12174137" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Improvement of psoriasis during imatinib therapy in a patient with a metastatic gastrointestinal stromal tumour.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12614232" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : A spectrum of skin reactions caused by the tyrosine kinase inhibitor imatinib mesylate (STI 571, Glivec).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28398413" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Imatinib mesylate-induced lichenoid drug eruption.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18936416" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Imatinib-induced hand-foot syndrome in a patient with metastatic gastrointestinal stromal tumor.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25637330" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Incidence and risk of xerosis with targeted anticancer therapies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18550575" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Hand foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinib.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18998055" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Blackberry-induced hand-foot skin reaction to sunitinib.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18645140" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Prospective study of the cutaneous adverse effects of sorafenib, a novel multikinase inhibitor.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18054825" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Toxicities associated with the administration of sorafenib, sunitinib, and temsirolimus and their management in patients with metastatic renal cell carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18210295" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Risk of hand-foot skin reaction with sorafenib: a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17215530" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Sorafenib in advanced clear-cell renal-cell carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30991119" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Risk of hand-foot skin reaction associated with vascular endothelial growth factor-tyrosine kinase inhibitors: A meta-analysis of 57 randomized controlled trials involving 24,956 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26009777" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Incidence and risk of hand-foot skin reaction with cabozantinib, a novel multikinase inhibitor: a meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25482593" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Risk of mucocutaneous toxicities in patients with solid tumors treated with sunitinib: a critical review and meta analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21507035" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Meta-analysis of dermatological toxicities associated with sorafenib.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17179114" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Hand-foot syndrome and seborrheic dermatitis-like rash induced by sunitinib in a patient with advanced renal cell carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19116896" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Sodium oxybate relieves pain and improves function in fibromyalgia syndrome: a randomized, double-blind, placebo-controlled, multicenter clinical trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26387145" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Alopecia in patients treated with molecularly targeted anticancer therapies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22056247" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20100962" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28189432" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Risk of Distinctive Hair Changes Associated With Pazopanib in Patients With Renal Cell Carcinoma (RCC) Versus Patients Without RCC: A Comparative Systematic Review and Meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20516434" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Profound hair and skin hypopigmentation in an African American woman treated with the multi-targeted tyrosine kinase inhibitor pazopanib.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19597016" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Keratoacanthomas and squamous cell carcinomas in patients receiving sorafenib.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19213663" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : Cutaneous squamous cell carcinoma and inflammation of actinic keratoses associated with sorafenib.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17190642" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : Keratoacanthomas associated with sorafenib therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18559769" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : Multiple squamous cell carcinomas of the skin after therapy with sorafenib combined with tipifarnib.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19660024" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : Eruptive keratoacanthoma-type squamous cell carcinomas in patients taking sorafenib for the treatment of solid tumors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19700018" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : The histologic spectrum of epithelial neoplasms induced by sorafenib.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20004316" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : [Sorafenib-induced multiple eruptive keratoacanthomas].
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18559790" id="rid92" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          93 : Sorafenib-induced eruptive melanocytic lesions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23677103" id="rid93" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          94 : Eruptive melanocytic nevi in a patient undergoing treatment with sunitinib.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23576484" id="rid94" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          95 : Geographic tongue induced by angiogenesis inhibitors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22782962" id="rid95" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          96 : Erythema multiforme induced by sorafenib for metastatic renal cell carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22134572" id="rid96" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          97 : Erythema multiforme-like drug reaction to sorafenib.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26422655" id="rid97" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          98 : Sorafenib-Induced Eruption Mimicking Erythema Multiforme.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18209189" id="rid98" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          99 : Sunitinib: a cause of bullous palmoplantar erythrodysesthesia, periungual erythema, and mucositis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25209374" id="rid99" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          100 : Acquired perforating dermatosis associated with sorafenib therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19028406" id="rid100" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          101 : Dermatologic symptoms associated with the multikinase inhibitor sorafenib.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21220606" id="rid101" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          102 : Pyoderma gangrenosum with the use of sunitinib.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20877540" id="rid102" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          103 : A Second Case of Sunitinib-associated Pyoderma Gangrenosum.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18489600" id="rid103" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          104 : Pyoderma gangrenosum: another cutaneous side-effect of sunitinib?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20065189" id="rid104" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          105 : Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20371662" id="rid105" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          106 : Vandetanib (100 mg) in patients with locally advanced or metastatic hereditary medullary thyroid cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21282542" id="rid106" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          107 : Phase III trial of vandetanib compared with erlotinib in patients with previously treated advanced non-small-cell lung cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17878480" id="rid107" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          108 : Phase II study of vandetanib or placebo in small-cell lung cancer patients after complete or partial response to induction chemotherapy with or without radiation therapy: National Cancer Institute of Canada Clinical Trials Group Study BR.20.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22370318" id="rid108" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          109 : Vandetanib Versus placebo in patients with advanced non-small-cell lung cancer after prior therapy with an epidermal growth factor receptor tyrosine kinase inhibitor: a randomized, double-blind phase III trial (ZEPHYR).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2202514" id="rid109" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          110 : Epidermal cell kinetics of the pig: a review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23247489" id="rid110" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          111 : A new spectrum of skin toxic effects associated with the multikinase inhibitor vandetanib.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22346274" id="rid111" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          112 : Stevens-johnson syndrome induced by vandetanib.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22346274" id="rid112" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          113 : Stevens-johnson syndrome induced by vandetanib.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23177514" id="rid113" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          114 : Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24002501" id="rid114" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          115 : Cabozantinib in progressive medullary thyroid cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25427282" id="rid115" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          116 : Cutaneous adverse effects associated with the tyrosine-kinase inhibitor cabozantinib.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33021006" id="rid116" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          117 : Dermatologic Adverse Events Associated with Selective Fibroblast Growth Factor Receptor Inhibitors: Overview, Prevention, and Management Guidelines.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23276366" id="rid117" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          118 : Cutaneous toxicities of RAF inhibitors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30280426" id="rid118" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          119 : Systematic review and meta-analysis of prevalence of dermatological toxicities associated with vemurafenib treatment in patients with melanoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30601209" id="rid119" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          120 : BRAF Inhibitor-Associated Granulomatous Dermatitis: A Report of 3 Cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22296092" id="rid120" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          121 : Ultraviolet A and photosensitivity during vemurafenib therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23918947" id="rid121" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          122 : Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26200476" id="rid122" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          123 : Cutaneous Toxic Effects of BRAF Inhibitors Alone and in Combination With MEK Inhibitors for Metastatic Melanoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22804352" id="rid123" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          124 : Cutaneous manifestations of dabrafenib (GSK2118436): a selective inhibitor of mutant BRAF in patients with metastatic melanoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22256804" id="rid124" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          125 : RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25748298" id="rid125" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          126 : Factors influencing the development of cutaneous squamous cell carcinoma in patients on BRAF inhibitor therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30219628" id="rid126" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          127 : Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30219628" id="rid127" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          128 : Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29573941" id="rid128" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          129 : Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22356324" id="rid129" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          130 : Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30924242" id="rid130" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          131 : Evaluation of cutaneous adverse events of encorafenib and binimetinb: COMMENT on article by Graf et al.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21639808" id="rid131" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          132 : Improved survival with vemurafenib in melanoma with BRAF V600E mutation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid132" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          133 : BRIM-2: An open-label, multicenter phase II study of vemurafenib in previously treated patients with BRAF V600E mutation-positive metastatic melanoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25251629" id="rid133" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          134 : Pyogenic granuloma as a cutaneous adverse effect of vemurafenib.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25773419" id="rid134" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          135 : RASopathic alopecia: hair changes associated with vemurafenib therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22735384" id="rid135" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          136 : Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23699661" id="rid136" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          137 : Vemurafenib and radiosensitization.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23406731" id="rid137" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          138 : Prospective study of cutaneous side-effects associated with the BRAF inhibitor vemurafenib: a study of 42 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26412570" id="rid138" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          139 : Vemurafenib-induced toxic epidermal necrolysis: possible cross-reactivity with other sulfonamide compounds.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25384395" id="rid139" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          140 : Successful switch to dabrafenib after vemurafenib-induced toxic epidermal necrolysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24359127" id="rid140" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          141 : Toxic epidermal necrolysis in a patient receiving vemurafenib for treatment of metastatic malignant melanoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24359127" id="rid141" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          142 : Toxic epidermal necrolysis in a patient receiving vemurafenib for treatment of metastatic malignant melanoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24359127" id="rid142" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          143 : Toxic epidermal necrolysis in a patient receiving vemurafenib for treatment of metastatic malignant melanoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23248257" id="rid143" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          144 : Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22663011" id="rid144" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          145 : Improved survival with MEK inhibition in BRAF-mutated melanoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25399551" id="rid145" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          146 : Improved overall survival in melanoma with combined dabrafenib and trametinib.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28475671" id="rid146" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          147 : Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28475671" id="rid147" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          148 : Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30849534" id="rid148" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          149 : The relation between PI3K/AKT signalling pathway and cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30849534" id="rid149" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          150 : The relation between PI3K/AKT signalling pathway and cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30849534" id="rid150" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          151 : The relation between PI3K/AKT signalling pathway and cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30849534" id="rid151" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          152 : The relation between PI3K/AKT signalling pathway and cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30849534" id="rid152" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          153 : The relation between PI3K/AKT signalling pathway and cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30849534" id="rid153" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          154 : The relation between PI3K/AKT signalling pathway and cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36227613" id="rid154" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          155 : Incidence of Cutaneous Adverse Events With Phosphoinositide 3-Kinase Inhibitors as Adjuvant Therapy in Patients With Cancer: A Systematic Review and Meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29233821" id="rid155" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          156 : Activity of the PI3K-δ,γinhibitor duvelisib in a phase 1 trial and preclinical models of T-cell lymphoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30033575" id="rid156" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          157 : Duvelisib, an oral dual PI3K-δ,γinhibitor, shows clinical activity in indolent non-Hodgkin lymphoma in a phase 1 study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29179250" id="rid157" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          158 : PI3K Inhibitors: Understanding Toxicity Mechanisms and Management.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28633365" id="rid158" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          159 : Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31091374" id="rid159" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          160 : Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31091374" id="rid160" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          161 : Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31091374" id="rid161" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          162 : Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31091374" id="rid162" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          163 : Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31091374" id="rid163" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          164 : Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33222197" id="rid164" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          165 : Second primary malignancy in myelofibrosis patients treated with ruxolitinib.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37437151" id="rid165" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          166 : Cutaneous Squamous-Cell Carcinoma after Treatment with Ruxolitinib or Belumosudil.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37437151" id="rid166" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          167 : Cutaneous Squamous-Cell Carcinoma after Treatment with Ruxolitinib or Belumosudil.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37437151" id="rid167" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          168 : Cutaneous Squamous-Cell Carcinoma after Treatment with Ruxolitinib or Belumosudil.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37437151" id="rid168" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          169 : Cutaneous Squamous-Cell Carcinoma after Treatment with Ruxolitinib or Belumosudil.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35523374" id="rid169" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          170 : Ibrutinib-associated dermatologic toxicities: A systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32613545" id="rid170" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          171 : Dermatological Toxicities of Bruton's Tyrosine Kinase Inhibitors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32613545" id="rid171" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          172 : Dermatological Toxicities of Bruton's Tyrosine Kinase Inhibitors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid172" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          173 : Ibrutinib-Associated Rash: Single-Center Experience of Clinicopathologic Features and Management
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25138588" id="rid173" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          174 : Ibrutinib inhibits collagen-mediated but not ADP-mediated platelet aggregation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26430171" id="rid174" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          175 : Incidence and risk factors of bleeding-related adverse events in patients with chronic lymphocytic leukemia treated with ibrutinib.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26982511" id="rid175" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          176 : Hair and Nail Changes During Long-term Therapy With Ibrutinib for Chronic Lymphocytic Leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31870917" id="rid176" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          177 : Cutaneous eruptions from ibrutinib resembling epidermal growth factor receptor inhibitor-induced dermatologic adverse events.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26182170" id="rid177" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          178 : Panniculitis in Patients Undergoing Treatment With the Bruton Tyrosine Kinase Inhibitor Ibrutinib for Lymphoid Leukemias.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28953011" id="rid178" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          179 : Self-limiting Ibrutinib-Induced Neutrophilic Panniculitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28953011" id="rid179" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          180 : Self-limiting Ibrutinib-Induced Neutrophilic Panniculitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31334834" id="rid180" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          181 : Depletion of regulatory FoxP3+ T cells in the pathogenesis of Stevens-Johnson syndrome induced by mogamulizumab.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23687091" id="rid181" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          182 : FLT3 inhibitor-induced neutrophilic dermatosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23687091" id="rid182" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          183 : FLT3 inhibitor-induced neutrophilic dermatosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31665578" id="rid183" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          184 : Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31665578" id="rid184" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          185 : Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33287892" id="rid185" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          186 : FLT3 inhibitors in acute myeloid leukaemia: assessment of clinical effectiveness, adverse events and future research-a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26886840" id="rid186" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          187 : FLT3 Inhibitor-Associated Neutrophilic Dermatoses.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33632926" id="rid187" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          188 : FDA Approval Summary: Gilteritinib for Relapsed or Refractory Acute Myeloid Leukemia with a FLT3 Mutation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29860938" id="rid188" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          189 : Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27245312" id="rid189" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          190 : Evidence for Clinical Differentiation and Differentiation Syndrome in Patients With Acute Myeloid Leukemia and IDH1 Mutations Treated With the Targeted Mutant IDH1 Inhibitor, AG-120.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27245312" id="rid190" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          191 : Evidence for Clinical Differentiation and Differentiation Syndrome in Patients With Acute Myeloid Leukemia and IDH1 Mutations Treated With the Targeted Mutant IDH1 Inhibitor, AG-120.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27245312" id="rid191" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          192 : Evidence for Clinical Differentiation and Differentiation Syndrome in Patients With Acute Myeloid Leukemia and IDH1 Mutations Treated With the Targeted Mutant IDH1 Inhibitor, AG-120.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29562156" id="rid192" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          193 : Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35274723" id="rid193" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          194 : Management of Dermatologic Events Associated With the Nectin-4-directed Antibody-Drug Conjugate Enfortumab Vedotin.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
